



# Fair Pricing Forum 2021

Meeting Report



## Fair Pricing Forum 2021 meeting report



**World Health  
Organization**

Fair pricing forum 2021 meeting report

ISBN 978-92-4-003858-5 (electronic version)

ISBN 978-92-4-003859-2 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** Fair pricing forum 2021 meeting report. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the report of the Fair Pricing Forum 2021 and does not necessarily represent the decisions or policies of WHO.

# Contents

Contents .....	iii
Acknowledgements .....	iv
Executive summary .....	1
Overview.....	1
Main themes from the Forum.....	1
Next steps .....	1
Overview.....	2
Background .....	2
Forum objectives and agenda .....	2
At the Forum .....	2
Main themes arising from the Forum.....	3
Transparency is essential for improving access to current and future innovations.....	3
Collaboration across countries can facilitate affordable access .....	3
The public sector could play a greater role in ensuring affordability and driving future innovations.....	3
Stakeholders must clarify definitions and metrics of affordability.....	4
Further policymaking is needed to ensure affordable access to medical devices and in vitro diagnostics .....	4
Session summaries.....	5
Plenary sessions.....	5
Parallel sessions .....	8
References.....	17
Annex 1: List of Forum participants.....	17
Annex 2: Forum agenda .....	42
Annex 3: Members of Fair Pricing Forum 2021 preparatory working groups.....	50

# Acknowledgements

The Fair Pricing Forum 2021 was made possible through a collaboration among members of secretariats at the Ministry of Health of the Government of Argentina, Pan American Health Organization, and the Department of Health Products Policy and Standards of the World Health Organization (WHO).

WHO would like to express special thanks to members of the two technical preparatory working groups, as well as the speakers, panellists and participants who provided rich contributions to the Forum. These contributors can be found in Annexes to this document.

# Executive summary

## Overview

The third biennial Fair Pricing Forum was held online on 13-15 and 20-22 April 2021 to continue the tradition of encouraging dialogue among various stakeholders, with the following objectives:

- i. To share countries' experiences, including from the coronavirus disease (COVID-19) pandemic, in ensuring affordability and transparency of prices and costs of health products
- ii. To advance discussion and knowledge on approaches and system factors pertaining to the pricing and R&D of pharmaceutical products for enhancing affordability, transparency, and innovation, and achieving health sustainable development goals
- iii. To increase support for countries to achieve more affordable and fairer access to pharmaceutical products during the COVID-19 pandemic and beyond.

In total, more than 850 people from 125 Member States participated in the Forum and pre-Forum webinar.

## Main themes from the Forum

- Transparency is essential for improving access to current and future innovations to inform and enforce pricing and innovation policies, as well as ensure accountability
- Collaboration across countries can facilitate affordable access by leveraging collective positions, joint technical assessments and decision-making, and sharing market information
- Interest is growing for the public sector to play a greater role in ensuring affordability and driving innovation
- Stakeholders must clarify definitions and metrics of affordability to facilitate global discourse on access
- Further policymaking is needed to ensure affordable access to medical devices and in vitro diagnostics, with unique and complex market features compared to medicines/vaccines markets

## Next steps

Additional work is needed to accelerate access to effective health products and ensure prices are affordable to health systems and patients. This includes making better use of the collective power of countries, investing in innovation to meet public health needs, determining the true value of health products, and efficient regulatory processes and legal tools to improve early access and affordability. Learnings from the COVID-19 pandemic in accelerating development and access can contribute to longer-term solutions to many of these challenges.

Specific areas for further stakeholder action are highlighted throughout the document. Key WHO activities planned before the next Fair Pricing Forum in 2023 include:

- Create a knowledge hub for stakeholders to reach experts, share views and information on how to improve availability, pricing, and affordability of health technologies with increasing impact on access
- Launch an updated electronic tool, MedMon, designed to monitor availability and prices of health products in countries, as open access and available to all
- Support the development of national or regional price monitoring systems
- Strengthen capacity building of national policy makers by hosting further webinars and trainings

# Overview

## Background

In 2019, World Health Assembly resolution WHA72(8) *Improving the transparency of markets for medicines, vaccines, and other health products* requested the WHO Director-General, among other requests, “to continue WHO’s efforts to biennially convene the Fair Pricing Forum with Member States and all relevant stakeholders to discuss the affordability and transparency of prices and costs relating to health products”.

The 2021 Forum was held under this mandate to continue the tradition of encouraging rich dialogue among various stakeholders, following the first Forum in Amsterdam (The Netherlands) in 2017, and the second Forum in Johannesburg (South Africa) in 2019.

## Forum objectives and agenda

The Forum agenda was informed by three objectives:

- i. To share countries’ experiences, including from the coronavirus disease (COVID-19) pandemic, in ensuring affordability and transparency of prices and costs of health products
- ii. To advance discussion and knowledge on approaches and system factors pertaining to the pricing and R&D of pharmaceutical products for enhancing affordability, transparency, and innovation, and achieving health sustainable development goals
- iii. To increase support for countries to achieve more affordable and fairer access to pharmaceutical products during the COVID-19 pandemic and beyond.

The Forum was organized with the support from the Government of Argentina. Two preparatory working groups of experts contributed to the contents of the agenda, including two discussion papers.

## At the Forum

The Forum was held online on 13-15 and 20-22 April 2021. In total, more than 850 people from 125 Member States registered to participate in the Forum and pre-Forum webinar. Over the event, more than 150 speakers, panellists and moderators contributed to 14 plenary sessions, parallel sessions, and pre-Forum webinar, as illustrated below.

Figure 1: Fair Pricing Forum 2021 in numbers





# Main themes arising from the Forum

## Transparency is essential for improving access to current and future innovations

Improving the transparency of pharmaceutical markets is the central tenet of World Health Assembly resolution WHA72(8). Forum participants re-affirmed the importance of transparency as the unifying principle in solving various problems relating to pricing, access and innovation. These include using price transparency to inform better pricing policy design, using cost transparency to inform investigations into potential excessive pricing practice, and using transparent contractual terms for research and development projects to facilitate accountability and affordability of health innovations.

Additional work is needed to ensure that the right information reaches the right stakeholders in a timely manner to enable the right decisions to ensure access. While transparency is generally a good governance principle, market transparency must not be overly onerous such that it stifles the very innovation and access it is meant to aid. Work is underway to define and gather information required for informing and enforcing pricing and innovation policies, as well as ensuring accountability.

## Collaboration across countries can facilitate affordable access

While there are certainly differences in individual markets, there is significant opportunity for cooperation among countries to facilitate affordable access. These include leveraging the

collective positions of countries to bring about affordable pricing and reduction in supply costs, joint technical assessments and decision-making, and sharing market information to curb excessive pricing.

Collaborations with and between governments, international organizations and other stakeholders are essential to further enable both innovation and access. Public-private collaborations might be particularly beneficial for improving access to medicines for neglected diseases. However, public-private collaboration needs clear governance mechanisms to avoid conflicts of interest.

## The public sector could play a greater role in ensuring affordability and driving future innovations

There were calls for greater roles and oversight of policies by the public sector to ensure affordable access to health products and driving future innovations. While recognizing the important roles of the private sector and competitive market mechanisms in improving affordability of health products and innovation, a need for public stewardship was emphasized across multiple Forum sessions.

As health budgets become more constrained across countries at all income levels, the public sector that in the past may have successfully functioned as payer needs to become a more prudent purchaser and investor in health technologies and services. These range from devising better pricing policies to rethinking how innovation models could be reorganized to better serve public health need

## **Stakeholders must clarify definitions and metrics of affordability**

The operationalization of affordability has been noted to be difficult because of its subjective nature. Nonetheless, discussion at the Forum highlighted a need to clarify affordability, including whether countries with different levels of income and health budgets could come to a common definition of affordability for facilitating global discourse on affordable access. Such a common understanding on affordability could potentially yield more objective metrics for assessing fair pricing.

Some argue that a broader perspective is needed with respect to the concept of affordability: not only to focus on the cost of medicines, but on patient outcomes and the economic context. The Forum heard some proposed approaches to assess the affordability of health products. One option discussed was a “health opportunity cost” approach, where a range of within- and cross-country data would be used to inform the assessment of pricing and affordability. There was also a discussion of how pricing and affordability metrics should account for clinical uncertainty at various points in the product lifecycle.

## **Further policymaking is needed to ensure affordable access to medical devices and in vitro diagnostics**

The 2021 Forum included for the first time a discussion on affordable access to medical devices and in vitro diagnostics, reflecting the growing need to ensure affordable access to all health products. The discussion recognized different features and high complexity of medical

devices & in vitro diagnostics markets compared to medicines/vaccines markets.

It is complex to negotiate fair prices that cover the device cost, reagents and other consumables, maintenance, and technical support costs. Procurement often focuses on capital costs without considering operating costs. It remains challenging to create a lifecycle budget that fully estimates the total operational costs, however participants highlighted opportunities for further development of specific pricing and value assessments to ensure fair pricing

# Session summaries

## Plenary sessions

### PL1: The need for Global Public Goods and affordable access for all in the time of COVID-19 pandemic and beyond

The 2021 Forum was opened by Dr Carissa Etienne, Director of Pan American Health Organization and Regional Director of WHO Regional Office for the Americas; Dr Mariângela Simão, Assistant Director General for Access to Medicines and Health Products at WHO Headquarters; and Dr Carla Vizzotti, Honorable Minister of Health of the Republic of Argentina. Together they called for upholding the principles of equity and social justice in prioritizing access to essential health products, including affordable pricing, particularly in these extraordinary times during the COVID-19 pandemic.

Several speakers highlighted the importance of market transparency in achieving a balance between promoting innovation and patient access to health products. They also acknowledged the importance of transparency in building public confidence in the health systems. Collaborations with and between governments, international organizations and other stakeholders are essential, recognizing the importance of the Fair Pricing Forum and initiatives such as the Oslo Medicines Initiative for fostering such collaboration. They reflected on

the lessons learnt from the COVID-19 pandemic and called for alternative model for innovation and equitable access to global public goods (e.g., COVID-19 vaccines), not just from a health perspective but also from an economic security perspective. These include ensuring pricing that accounts for public contribution to R&D, and the application of intellectual property rights towards affordable access.

Representatives from the medical device, generic and biosimilar, and biopharmaceutical industries echoed the importance of collaboration in seeking solutions for making health products affordable and accessible. They described industry's roles in facilitating innovation and access, including during the COVID-19 pandemic. They highlighted the characteristics of their respective sector, including complexity of the industry structures, contributions to product affordability, and innovation. They urged greater partnership among stakeholders to solve the access problems, including but not limited to, removing trade barriers, maintaining an open supply chain, as well as fair pricing and ample budget.

### PL2: Looking back and looking forward on national transparency initiatives, pricing policy reforms and role of stakeholders

Panellists in this session described various policy responses to achieve affordable pricing, greater transparency of the markets and stakeholder engagements. These included (1) cross-sectoral policy responses with a mix of interventions

across taxation, value assessments, price regulation, strategic procurements in Ghana; (2) the policies in Italy on discounts for generic and biosimilar medicines, and the 2020 price setting and reimbursement decree that mandated full disclosure of public contribution to R&D funding,

intellectual property rights, and prices in the European Union to the government; (3) use of direct price regulation as well as internal and external reference pricing in Sri Lanka; and (4) the use of health technology assessment to inform the pricing of on-patent medicines and volume-based pricing for off-patent medicines in China (which had achieved greater than 50% price reduction).

Some panellists highlighted the problems associated with a lack of price transparency (e.g., unfair negotiation due to a lack of information for one party, and lack of accountability). They called for greater transparency. These included the use of health technology assessment, applying conditions for procurements by public sector managers, and disclosure of information through legislative measures, and attaching disclosure

requirements as a condition for R&D funding. There were also suggestions for using pooled procurement mechanisms to leverage collective purchasing power.

Representative from the generic and biosimilar industry noted the challenging business environment when countries applied external reference pricing for generic and biosimilar medicines based on disclosed list prices without considering local market contexts. While acknowledging the need for pricing policy reform, it was noted that excessive market consolidation for off-patent medicines as a result of reform might reduce market competitiveness in the long run.

### **PL3: Moving towards fair prices by public health-driven application and management of Intellectual Property**

This plenary session discussed intellectual property as a tool to achieve public policy objectives, namely, to accelerate the development and manufacturing of products for COVID-19. The pandemic has raised issues at the crossroads of public health, intellectual property, and trade since its beginning. Collaborative efforts are encouraged and strive to simultaneously address innovation and access needs.

The session heard about various international initiatives related to the application and management of intellectual property to promote equitable access to COVID-19 health technologies, including voluntary sharing initiatives such as C-TAP (COVID-19 Technology Access Pool). The panelists emphasized the importance of having multiplicity of mechanisms to facilitate access and scale up production. These include licensing and technology transfer, TRIPS flexibilities, competition law/policy and

where necessary, intellectual property waivers. They also emphasized the need for further work on pro-access Terms and Conditions in R&D funding agreements.

To fully empower the management of intellectual property, the panelists had noted various challenges that would need to be mitigated. First, they emphasized the need for unveiling public information around vaccine prices, licensing/technology transfer agreements, R&D/production costs, volumes of production, distribution, regulatory information, and patent status information. They also noted considerable difficulties with applying TRIPS flexibilities in practice. Finally, technology transfer and capacity for technical knowledge should be enhanced to diversify supplies and increase competition. Many options must come together to effectively address the need for COVID-19 health technologies and to ensure diversity of supply.

#### PL4: "Breaking barriers to access and affordability: Need for concerted global action"

This concluding session heard insights from government host representatives of the current and prior Fair Pricing Fora, and the four Chairs of the two preparatory working groups for the Fair Pricing Forum 2021.

The panellists noted a need for creating a more balanced and cooperative system between public and private actors to bring about affordable and equitable access to health products and innovations that serves public health goals.

Such a system would require greater level of public sector leadership than the status quo. It would require broad-based approach to achieve transparency of market, diversified and more reliable production chains, and stronger competition. It would also require the reconsideration of pricing approaches to bring about more affordable pricing and to mitigate the risks of excessive pricing. Pricing of medicines must align with how much a health care system can afford to pay for the additional benefits the medicine offered. The approach of value-based pricing, as it is currently used for pricing new

medicines, was noted as not sustainable. There was also a call for greater consideration of reducing health inequity in health technology assessment.

On the innovation front, there were proposals of a "mission-oriented system of innovation" that will deliver life-saving medicines to those in need at affordable prices. It sought a coordinated end-to-end system led by the public sector that moves "beyond the drug-by-drug, deal-by-deal, push and pull incentive to real public sector stewardship, from access conditions to public sector procurement and production, and to supporting new institutions."

The 2021 Forum closed following concluding remarks from Dr Carla Vizzotti, Honorable Minister of Health of the Republic of Argentina; Dr Philippe Duneton, Executive Director of Unitaïd; and Dr Mariângela Simão, Assistant Director General for Access to Medicines and Health Products at WHO Headquarters.

## Parallel sessions

### PS1: Cross-border collaborative initiatives to bring about more affordable pricing of vaccines & medicines

This session aimed to revisit various aspects of cross-border initiatives to bring about more affordable pricing of vaccines and medicines, with the purpose of exploring feasible options for further enabling these initiatives.

#### Opportunities

The collaborative initiatives presented in this session were founded on a mutual understanding of values, access principles and affordability, as well as a common vision for achieving affordable access among participating members. Success factors included strong political will, clear goals, willingness to modify policies or arrangements during implementation.

The discussion highlighted various advantages of cross-border collaboration. These included allowing the procurers to leverage their collective position to bring about affordable pricing and reduction in supply costs. Joint decision-making and joint reports at the level of a collaboration also added more value to participating members, built trust by the public, and provided greater negotiating stance. Overall, these initiatives had shown to improve access to medicines in participating countries.

In general, cross-border supply initiatives had benefitted from longer-term demand commitment, and budget management supported by a financing mechanism (e.g., UNICEF supply of vaccines for middle income countries). It was also noted that public–private collaborations might be particularly beneficial for improving access to medicines for neglected diseases. However, public-private sector collaboration needs clear governance mechanisms to avoid conflicts of interest.

#### Challenges

To effectively pool demand and increase purchasing power, countries would need to be able to undertake multi-year demand forecasting, as suppliers would be reluctant to engage in short-term contracts and in small supply quantities. Some countries might have limited capacity for undertaking demand forecasting.

Markets for health products function differently. Markets for and markets for single-source and off-patent products also have different market requirements. This means that assessment, pricing, and procurement would need to be tailored to each type of product. In some cases, the effectiveness of pooled procurement and joint negotiation may be reduced due to countries' specific product preferences.

Establishing governance mechanisms and joint international processes can be difficult, especially when pricing legislations and procurement differ.

#### Topics for further exploration

1. What can we learn from the successes and failures of joint procurement of COVID-19 products, especially vaccines?
2. Can countries with various levels of income and health care need agree on a common definition of affordability? Can this definition be the basis for differential pricing, including a global differential pricing approach? What is the evidence of the impact of differential pricing on improving access to medicines?
3. To what extent should prices and procurement contracts be transparent? How would such transparency impact on parallel trade and external reference pricing?

## PS2: Promoting transparency for accountable medical innovation

This session aimed to clarify the utility and potential processes for achieving transparency of innovation incentives, including requirements imposed by procurement agencies and funders to government regulatory requirements.

WHO Member States recognized the importance of improving the transparency of markets for health products in WHA72.8 in 2019. This Resolution recognizes the importance of both public- and private-sector funding for research and development of health products. In seeking to improve the transparency of such funding across the value chain, it is therefore important to monitor the impacts of such transparency on affordability and availability of health products.

In the African experience, the lack of transparency restricts access to medicines, including those for chronic and neglected diseases, due to costs and geographic inequity. Japan creates an incentive for companies to disclose cost components to the greatest extent possible, which allows for comparative pricing between medicines. The emergence of tools to evaluate fairness such as the AIM Fair Pricing Model, the Transparency Checklist from the Observatoire Transparence Médicaments and the Access to Medicines Index represents a growing opportunity, though participants cautioned that use of such information should not discourage investment

### Opportunities

- Broad support for disclosure of public R&D funding, R&D costs, prices charged by companies, manufacturing costs, and trial results
- Collection and analysis of publicly accessible data and legislative, regulatory, and judicial measures are potential levers to increase transparency
- Government can create incentives for companies to disclose price components

- Transparency may permit a greater understanding of the innovation and risk assumed by various stakeholders
- Transparent open science norms can enable the right innovations for public health priorities at fairer prices

### Challenges

- Lack of transparent data on inputs across the value chain, including clinical trials, can lead to hesitancy on the part of regulators and patients on applicability of a medicine to their population
- Despite an increase in use of access and affordability strategies by industry, progress is still gradual in terms of scope of products and geographic coverage
- Comparability of price and cost elements across health systems
- Remaining concerns about increased transparency but continued dialogue on good practice seen as key to ensuring equity of access and fair pricing

### Topics for further exploration

- Standard setting and data systems needed for transparency of inputs throughout the value chain, including procurement and distribution
- Further analysis and dialogue on the relationships between cost, price, and value of a health product and the utility of emerging tools to evaluate them
- How can transparency strengthen established good practice such as equitable pricing, licensing, and structured donation programs?
- How can legitimate concerns about increased information transparency be addressed and potential negative impacts mitigated?
- Establishing good practice in clinical trial diversity to aid in rapid deployment of effective new medicines.

### PS3: Fair pricing and affordability of medical devices including in vitro diagnostics

This session focused on challenges faced by countries when trying to achieve affordable pricing information of medical health technologies, such as CT scanners, glucose monitoring, and oxygen delivery systems.

The session highlighted the complexity of negotiating fair prices that cover the device cost, reagents and other consumables, maintenance, and technical support costs. Procurement often focuses on capital costs without considering operating expenses i.e., only capturing “the tip of the iceberg” in the pricing approach. This was cited as the case in Brazil, where a lack of transparency in procurement processes is seen as a determining factor in the high prices of medicines and medical products.

It remains challenging to create a lifecycle budget that fully estimates the total operational costs, as a participant from Benin noted the evaluation of medical devices cannot be done as it is in the pharmaceutical sector. Nevertheless, participants highlighted opportunities for further assessing value of technologies and frameworks for fair pricing.

#### Opportunities

- Standards on reporting price and cost components are in development that are relevant for medical devices and in vitro diagnostics to increase transparency
- There was a recognition of a need to develop a normative framework for fair pricing of medical devices and diagnostics
- Stakeholders can build on and use existing tools provided by WHO for medical technology selection, pricing, and reimbursement
- Health technology assessment and health technology management to support

assessments of value must further consider the unique aspects of the device lifecycle

#### Challenges

- Complex market dynamics for medical devices and diagnostics lead to a lack of a clear definition for affordability of medical devices
- Procurement focuses on capital cost without considering operating costs, maintenance services and consumables (the “tip of the iceberg” models)
- Harmonized nomenclature and classification to allow valid comparison of medical devices effectiveness and cost is currently lacking
- A lack of accurate and comparable data on prices and lifecycle costs limits capacity to negotiate fair pricing
- Health technology assessment capacity and collaboration across countries is currently limited

#### Topics for further exploration

- Development of methodology to support a framework for fair pricing of medical devices
- Further development of nomenclature and classification of medical devices to permit the interchangeability of information between countries
- Priority medical devices listing across additional therapeutic categories to assist Member States in selection, procurement, and maintenance
- Develop context-sensitive and evidence-based Total Cost-of Ownership models for essential medical devices
- How dependent are medical devices and their life cycle support dependent on regional and local context, including whether manufacturers are locally represented



## PS4: Fairness before the finish line: Placing access conditions on incentives for innovation

This session aimed to analyze experiences with conditional innovation incentives and key elements of success, potential applications to other contexts, and needed areas of engagement.

Representatives from DNDi, CEPI, and the Wellcome Trust identified opportunities such as access to R&D projects, collaboration agreements based on joint visions, product profiles that respond to the needs of the population, intellectual property policy with principles of equitable access, affordability, research results, drug development as public goods, and revenue sharing. Health systems have explored a series of conditional mechanisms such as push or pull financing, signaling a move from being a payer to becoming a more prudent purchaser and investor in health innovation, particularly when public money contributes to the development. For example, in Argentina the availability of funds for innovation projects is being evaluated, together with universities and government support for R&D.

### Opportunities

- Conditionalities can be an important instrument for ensuring fairer pricing and greater access to needed health technologies
- Significant public funding in R&D seen as a key catalyst for access conditions
- COVID-19 pandemic has presented opportunities for the public sector to be a better steward of its financing of health technologies that may apply to other health technologies or markets
- Alternative models for revenue sharing can allow public and philanthropic funders to attain return on investment
- Lessons in implementing health technology assessment: patient participation, price transparency, identifying value chain gaps

### Challenges

- Need to ensure that contingencies maintain adequate incentives for stakeholders to participate, common concern stated that conditions would stifle innovation
- Necessary to objectively identify gaps in the drug development process, and strike balance a true partnership and decentralizing risk responsibility
- Exchange must be forced through technology transfer and advance price commitments achieved
- A broader perspective is needed with respect to the concept of affordability: not only to focus on the cost of medicines, but on patient outcomes and the economic context

### Topics for further exploration

- Opportunities to expand South-South innovation capacity to meet public health needs at fairer prices
- Further analysis and dialogue on relationships between costs, affordability, patient outcomes, and economic context
- Ongoing dialogue at the TRIPS Council of the WTO regarding incentives for innovation and IP rights, especially on COVID-19 vaccines
- Role of the public sector in financing various stages of innovation, from R&D to product purchase: are governments “paying twice”?
- How to create incentives for competition rather than a simple cost-plus formula, which might disincentivize investments to improve manufacturing and supply chain efficiencies?
- What efforts contribute to securing better access conditions for the public good? Are such examples outliers or bellwethers?
- Transparency about who finances what, the conditions of participation in the initial stages of research, responsibility and accountability, availability to fulfill commitments

## PS5: Price and value of health products

This session aimed to discuss the benefits, drawbacks, and challenges of using value assessment in pricing based on country and stakeholder experiences. The panel aimed to assess if and how value assessment through health technology assessment (HTA) could be used more effectively for achieving affordable pricing in LMICs, and other HICs that had not established an HTA system. Panelists presented from their perspectives on what had been the impacts of value assessments on price and affordability, particularly in LMICs.

### Opportunities

The expansion of evidence informed pricing in lower income countries using HTA was noted in the session. There seemed to be a collective understanding that pricing informed by evidence, including value assessment, was a “rational” way of managing pricing and affordability.

Experiences from Brazil, France, Ghana, and Tunisia showed systems at various stages of development. Some systems used HTA to complement other pricing approaches, such as external reference pricing and price negotiation.

### Challenges

Various challenges pertaining to the use of value assessment through HTA to inform pricing were raised. One panelist expressed the opinion that value assessment had been and continued to be used primarily as an advocacy and lobbying tool and avoided addressing the real question: the discrepancies between the price of new medicines and the evidence of how much health systems around the world could afford to pay for the benefits the medicines offered. The panelist noted that any value assessment that did not attempt to capture the opportunity costs of what a health system would need to give up across all different elements of benefits could threaten

affordability and access to effective medicines globally. Indeed, another panelist noted the lack of relationship between value and price.

Other challenges noted include:

- A lack of clarity on objectives or the need for value assessment, in light of the differences in viewing “value by patients, health systems and societies, as well as the complex multi-stakeholder nature of value assessment and its associated multi-partner’s interests
- How to incorporate budget constraints in HTA
- A lack of resources and expertise needed to carry out rigorous assessments and processes, at frequency needed by health systems
- Limited models in the African context on the HTA institutionalization process
- How to assess the value of high-cost medicines and the frequent use of confidential managed entry agreements to facilitate access to these medicines
- Lack of submissions for neglected diseases, chronic diseases, and special groups
- Difficulties in recommending disinvestment of technologies

### Topics for further exploration

- Are the prices paid for high-cost medicines really reflect societal willingness to pay?
- How can government signal to the industry about the expected (cap on) returns on investment on R&D?
- How can value assessments fully capture opportunity costs of what would be given up by funding the innovative technology?
- Can a consensus about the attributes (beyond the simple public health objective) and their relative weights, be built to inform value assessment and pricing mechanism?

## PS6: Tools, standards and solutions for improving price transparency

This session focused on how to implement the provisions of WHA resolution 72.8, with a special focus on price transparency. Discussion included setting the norms and standards on reporting, such as internationally accepted terminology needed for reporting “net prices of health products”, and price related information that can allow valid international comparisons.

Discussion also focused on the key processes and elements of building a functional price information sharing platform for medicines and vaccines, and experiences and impacts at the national, regional, and global levels.

Finally, the session discussed which type of medicines price and reimbursement information would be most valuable to inform government pricing interventions, including negotiation with manufacturers. It also discussed the roles of governments, civil society and private sector on reporting and sharing price and related information.

### Opportunities

- Initiatives are emerging to develop price monitoring systems at national and regional levels and collect relevant price data to better understand market dynamics
- Global standards and tools to support price transparency initiatives and exchange of information are in development

- Governments are becoming increasingly accountable to citizens to explain how prices are achieved and what investments have been made
- Transparency initiatives must be effectively linked to other policies and initiatives to improve affordability and access

### Challenges

- Confidential price agreements with governments frequently prevent disclosure
- There may be conflicts of interest among various stakeholders participating in transparency efforts which require disclosure and mitigation
- Further guidance on reporting and comparison of price and related information is needed to enable implementation and utilization of transparency efforts

### Topics for further exploration

- Standardization of how to report and share price and price related information
- Feasibility and potential value of a web-based platform for sharing price and price related information
- Community of practice and analysis of pricing policies to facilitate transparency implementation

## PS7: Making the public sector more effective stewards of innovation and access

This session aimed to explore the viability of public sector-driven models that integrate R&D with manufacturing and distribution. The public pays a substantial role in funding innovation, either upfront for R&D or after innovations reach the market, plus building the human capital and capacity behind such innovation. This significant public investment could aid in aligning innovation with public health priorities and incentives for innovation to achieve fair prices.

Participants discussed recent examples of attempts for such alignment, such as the AMR Action Fund, or Thailand's collection of real-world evidence. Innovative business models are occurring in the private sector as well as non-profit companies. Panelists recognized that likely no single instrument could guarantee affordability and access, that different models may be necessary for different products.

### Opportunities

- The traditional role of the state has been fixing market failures, a broader framework to co-create innovation and co-shape markets could deliver better outcomes
- The public sector can play a more direct role, such as through procurement or production of key health commodities, to ensure effective stewardship to achieve fair pricing
- Panelists raised analogies from other sectors e.g., space exploration or defense where procurement contracts stipulate no excess profits, applicability to health innovation (during pandemic vs. other diseases)
- Non-profit alternatives can help pool purchasing and alleviate shortages for products with limited commercial viability but high public health need
- If countries prioritize essential medicines for national formularies, it may help free budget for innovation and sustainable production

### Challenges

- Much current pharmaceutical innovation occurs in high income countries, potential lack of regard for public health needs and health system contexts of LMICs
- Mobilizing funding for R&D is a long-term risky proposition not accounted for in many government budgets in a sustainable manner
- Critical to account for uncertainties for both buyer and seller to achieve a fair price
- Current patent systems often permit wide, strong, upstream applications which may inhibit affordable access (see Plenary 3 on IP)
- Traditional economic models measure profit and efficiency, while the COVID-19 pandemic has highlighted how investment in health affects all of society, and public interest must be centered throughout the value chain
- True breakthrough innovations are difficult to realize because we try to feed them into traditional pharmaceutical innovation models

### Topics for further exploration

- Further dialogue on aligning cost-effectiveness with affordability
- Role of WHO and other stakeholders in guiding research prioritization to invest public money in the biggest public health needs and using that money efficiently
- Relationships between diverse types of investors and the pricing of innovation
- Deepening collaborative discussions between Ministries of Health and agencies responsible for science, technology, innovation, and industry to bridge the divide between innovation and access
- Platforms to collect real-world evidence and policy tools for economic evaluation and revision of coverage and reimbursement
- Rethinking the model for development of potential repurposed products

## PS8: Regulating excessive pricing and returns along the supply and distribution chain

This session sought aimed to identify to what extent could government interventions through competition laws and pricing regulations address the risks of excessive pharmaceutical pricing, as well as whether additional instruments are needed to advance universal access to essential medicines and public welfare.

The panelists introduced the concept of excessive pricing as defined in competition laws. It was noted that unaffordable prices might reflect fundamental market changes, such as increased market concentration and reduced competition. Cases brought against potential excessive pricing were noted to be costly, lengthy, and risky, because of the (unnecessarily) complicated jurisprudence. High and excessive prices may also occur along the whole supply chain, e.g., due to excessive mark-ups and regulatory oversight.

### Opportunities

There was an increasing recognition of transparency in informing pricing policies and curbing excessive pricing practices, as it allowed benchmarking and accountability. To achieve this, the discussion noted the need to implement measures across the whole supply chain to improve transparency.

One panelist noted that greater efficiency across the supply chain could also be used to prevent high and excessive mark-ups. This could be achieved through shortening of the supply chain and a reduction in loyalty to branded pharmaceuticals or branded generics. To avoid excessive out-of-pocket costs by patients, governments in developing countries could focus increasingly on risk pooling and providing financial protection through insurance schemes.

It was noted that competition authorities should undertake studies cooperatively to better

understand the market, including comparing prices, marketing practices and economic analyses. Where required, competition authorities should enforce measures to stimulate competition, apply more stringent merger control, and to cooperate with sector regulators to carry out price controls, and other forms of direct market regulations as alternatives to competition law enforcement. Price control was noted as “more governance efficient than case-by-case competition law proceedings,” but such measures may need to consider potential “unintended consequences” (e.g., under-investment in the generic markets and partial application of the rules to specific products).

### Challenges

A lack of transparency due to confidential pricing and access agreements was noted as a hindering factor for informed decisions and accountability. These included impairing the authorities’ ability to ascertain whether a price was excessive or not.

Abuse of market power was noted as “very prevalent” (e.g., insulin market), but competition authorities had not offered swift solutions, in part due to a lack of capacity (e.g., in LMIC). Some panelists also suggested a need to review existing policies that had contributed to excessive pricing. These included abuses of intellectual property laws (e.g., ‘evergreening’ practices) and misuse of incentives for orphan drugs (e.g., use of ‘Insufficient return on investment’ criterion). The inefficiencies along the supply and distribution chains in LMICs would also need to be addressed.

### Topics for further exploration

- How can competition authorities better use their powers to collect information necessary to assess competitiveness of pricing practice?
- What are the deterrent effects of fines and investigations against anticompetitive practices?

## PS9: Judicialization of Health Care: Challenges and perspectives

This session focused on the reliance on courts and judicial processes to resolve litigations brought on by individuals to demand the provision of certain pharmaceuticals and medical treatments by the State based on rights-to-health claims.

The discussion examined the causes of the judicialization of health and its effects on health systems in Latin America, how health interventions and services could be prioritized with the support of laws, regulations, and scientific evidence, and if these are potential alternatives to judicialization.

### Opportunities

- Dialogue can educate stakeholders about the impacts of judicialization on social equity and health systems
- There is a need to increase transparency of decision-making processes on value assessment of new high-cost therapies
- Payers need more effective use of health technology assessment to ascertain health product effectiveness and value

### Challenges

- Unaffordable prices are often the result of a low ability to negotiate prices after court orders
- An increasing rate of judicialization over the last decades suggests that access and affordability should be addressed at a more systematic level
- Judicialization can highlight the difficult trade-offs among individual vs collective rights for access to medicines
- Inequitable access risks favoring the rich and educated and leaving behind the poor

- There are often conflicts of interest and a lack of transparency for health care providers and patient organizations involved in litigation proceedings

### Areas for further action

- Impact of judicialization on equity and use of limited resources
- Implications of providing access due to legal actions that are outside the usual public medicine management processes
- Strategies and tools to mitigate risks associated with increasing demand due to legal actions

## References

Prior to the Fair Pricing Forum 2021, a series of discussion papers were disseminated to Forum participants. These discussion papers do not represent an official position of WHO and were a tool to explore the views of participants on the subject matter.

- [Overview discussion paper for the Fair Pricing Forum 2021: Fair pricing in times of public health emergency and to accelerate achievements of Sustainable Development Goals health targets](#)
- [Forum discussion paper: Pricing approaches sensitive to health systems' ability to pay and the need for accelerating towards Health Sustainable Development Goal](#)
- [Forum discussion paper: Aligning incentives for pharmaceutical innovation to achieve fair pricing](#)

## Annexes

Annex 1: List of Forum participants

Annex 2: Forum agenda

Annex 3: Members of Fair Pricing Forum 2021 preparatory working groups

## Annex 1: List of participants

WHO Region	Reported Country	Full Name	Reported Affiliation
African Region	Angola	Mangueira, Katiza	Ministry of Health
African Region	Angola	Silva, Sara	Ministry of Health
African Region	Angola	Solino, José	Ministry of Health
African Region	Benin	Houngbo, Thierry	Ministry of Health
African Region	Burkina Faso	Gisèle, Sanou	Agence Béninoise de Régulation Pharmaceutique
African Region	Burkina Faso	Medah, Isaie	Ministry of Health
African Region	Burkina Faso	Sanou, Pascaline	Ministry of Health
African Region	Burkina Faso	Seini, Dr Emmanuel	Ministry of Health
African Region	Burkina Faso	Nadine, Traore	Mission Permanente of Burkina Faso
African Region	Burkina Faso	Ouédraogo, Wendegoudi Jacqueline	Mission Permanente of Burkina Faso
African Region	Burkina Faso	Sarassa, Aissatou	World Health Organization (WHO)
African Region	Cabo Verde	Do Rosário Centeio, Lenira	Entidade Reguladora Independente da Saúde (ERIS)
African Region	Cameroon	Djinou, Chantal	Ministry of Public Health
African Region	Cameroon	Hassan, Ben	Ministry of Public Health
African Region	Chad	Garandji, Daouda	Ministry of Public Health
African Region	Chad	Naibe Maimangyang, Saadié	Ministry of Public Health
African Region	Congo	Nikiema, Jean-Baptiste	World Health Organization (WHO)
African Region	Côte d'Ivoire	Koui, Isabelle	Ministry of Health
African Region	Democratic Republic of the Congo	Biayi, Franck	Ministry of Health
African Region	Democratic Republic of the Congo	Lunganga Mukendi, Tim	Ministry of Health
African Region	Eritrea	Alemu, Mulugeta	Ministry of Health
African Region	Eritrea	Tewolde, Tekle	Ministry of Health
African Region	Gabon	Okouyi Ndakissa, Edwige	Medicines Agency
African Region	Gambia	Janneh Kaira, Markieu	Medicines Control Agency
African Region	Ghana	Adjei Acquah, Elizabeth	Ministry of Health
African Region	Ghana	Asare, Brian	Ministry of Health
African Region	Ghana	Gavor, Edith	Ministry of Health
African Region	Ghana	Gyansa-Lutterodt, Martha	Ministry of Health
African Region	Ghana	Yevutsey, Saviour	Ministry of Health
African Region	Ghana	Ackon, Angela	World Health Organization (WHO)
African Region	Kenya	Mbau, Lilian	Kenya Cardiac Society
African Region	Madagascar	Mahavany, Nicole	Ministry of Public Health
African Region	Madagascar	Daniel, Ramananjahary	SALAMA National Medical Store
African Region	Mali	Dao, Abdoulaye	Ministry of Health and Social Development
African Region	Mauritius	Bohoorun, Jawaharduth	Ministry of Health and Wellness
African Region	Mauritius	Persand, Luvkishan	Ministry of Health and Wellness



WHO Region	Reported Country	Full Name	Reported Affiliation
African Region	Mauritius	Rumjaun, Nazeera	Ministry of Health and Wellness
African Region	Mauritius	Shaikh, Faisal	World Health Organization (WHO)
African Region	Mozambique	Manuel, Gilberto	Ministry of Health
African Region	Mozambique	Romeieque, Vangwaya	Ministry of Health
African Region	Mozambique	Mussá, Merana	National Directorate of Pharmacy
African Region	Namibia	Chaka, Brian	Namibia Association of Medical Aid Funds
African Region	Namibia	Tjiuoro, Stephen	Namibia Association of Medical Aid Funds
African Region	Namibia	Da Silva Mota, Magdalena	Namibian Association of Medical Aid Funds
African Region	Niger	Barira, Dan Nouhou	Ministry of Public Health
African Region	Niger	Saley, Daouda	Ministry of Public Health
African Region	Nigeria	Adeladan, Adenike	Federal Ministry of Health
African Region	Nigeria	Ajayi, Olubukola	Federal Ministry of Health
African Region	Nigeria	Hamzat, Omotayo	World Health Organization (WHO)
African Region	Senegal	Mangane, Abdoulahath	Ministère de la Santé et de l'Action sociale
African Region	South Africa	Meyer, Salomé	Cancer Alliance
African Region	South Africa	Gray, Andrew	Division of Pharmacology, University of KwaZulu-Natal
African Region	South Africa	Frittelli, Vivian	Generic and Biosimilar Medicines of Southern Africa
African Region	South Africa	Hwenda, Lenias	Medicines for Africa
African Region	South Africa	Pillay, Anban	National Department of Health
African Region	South Africa	Kitsa, Neo	Pricing Committee
African Region	South Africa	Da Gama, Mustaqeem	South African Permanent Mission to the World Trade Organization
African Region	South Africa	Suleman, Fatima	University of KwaZulu-Natal, South Africa
African Region	South Africa	Mueller, Jani	University of Pretoria
African Region	South Africa	Poluta, Mladen	Western Cape Government: Health
African Region	South Africa	Roy, Santie	Western Cape Government: Health
African Region	South Sudan	Baak, Peter	Drug and Food Control Authority
African Region	South Sudan	Ekoy, Bortel	Ministry of Health
African Region	South Sudan	Malual, Moses	Ministry of Health
African Region	Togo	Têko, Amoussou-Kouetete	Institut National d'Assurance Maladie
African Region	Uganda	Kibira, Denis	Coalition for Health Promotion and Social Development (HEPS-Uganda)
African Region	Uganda	Charles, Olaro	Ministry of Health
African Region	Uganda	Oteba, Okuna	Ministry of Health
African Region	United Republic of Tanzania	Msasi, Daudi	Ministry of Health
African Region	United Republic of Tanzania	Shija, Rose	World Health Organization (WHO)
African Region	Zimbabwe	Banda, Stephen	Ministry of Health and Child Care
African Region	Zimbabwe	Chigodo, Colline	Ministry of Health and Child Care
African Region	Zimbabwe	Madzikwa, Newman	Ministry of Health and Child Care
African Region	Zimbabwe	Annan, Edith	World Health Organization (WHO)
Eastern Mediterranean Region	Afghanistan	Yari, Asif	Food and Drug Administration
Eastern Mediterranean Region	Afghanistan	Saeed, Khwaja Mir Ahad	Ministry of Public Health
Eastern Mediterranean Region	Bahrain	Abdulmajeed, Areej	Ministry of Health

WHO Region	Reported Country	Full Name	Reported Affiliation
Eastern Mediterranean Region	Bahrain	Abdul Bary, Ahmed M	National Health Regulatory Authority
Eastern Mediterranean Region	Bahrain	Alalem, Lubna	National Health Regulatory Authority
Eastern Mediterranean Region	Bahrain	Husain, Sumaya	National Health Regulatory Authority
Eastern Mediterranean Region	Bahrain	Sakheer Alameeri, Yaser	Royal Medical Services
Eastern Mediterranean Region	Egypt	Farag, Sahar	Central Administration For Pharmaceutical Affairs - Ministry of Health and Population
Eastern Mediterranean Region	Egypt	Amine, Mohamed	Egyptian Drug Authority
Eastern Mediterranean Region	Egypt	Mady, Esraa	Egyptian Drug Authority
Eastern Mediterranean Region	Egypt	Naguib, Nesma	Egyptian Drug Authority
Eastern Mediterranean Region	Egypt	Zanaty, Suzan	Ministry of Health
Eastern Mediterranean Region	Egypt	Rachid, Dalia	Ministry of Health and Population
Eastern Mediterranean Region	Egypt	Al-Nuseirat, Adi	World Health Organization (WHO)
Eastern Mediterranean Region	Egypt	Elnahass, Nevine Sameh	World Health Organization (WHO)
Eastern Mediterranean Region	Egypt	Langar, Houda	World Health Organization (WHO)
Eastern Mediterranean Region	Iraq	Sirri, Alaa	KIMADIA
Eastern Mediterranean Region	Iraq	Mohammed, Evan	Ministry of Health
Eastern Mediterranean Region	Iraq	Nooruldeen, Zinah	World Health Organization (WHO)
Eastern Mediterranean Region	Jordan	Alhaqaish, Wesal	Food and Drug Administration
Eastern Mediterranean Region	Jordan	Almohtaseb, Heba	Goverment Procurement Department
Eastern Mediterranean Region	Jordan	Sboul, Hanan	Jordanian Association of Pharmaceutical Manufacturers
Eastern Mediterranean Region	Jordan	Al-Sadder, Anwar	World Health Organization (WHO)
Eastern Mediterranean Region	Lebanon	Metni, Mirna	ISPOR Lebanon
Eastern Mediterranean Region	Lebanon	Raidy, Colette	Ministry of Public Health
Eastern Mediterranean Region	Lebanon	Farah, Riad	Saint George Hospital
Eastern Mediterranean Region	Libya	Aljazwi, Marei	Ministry of Health
Eastern Mediterranean Region	Occupied Palestinian Territory, including east Jerusalem	Abu Safat, Atef	Ministry of Health

WHO Region	Reported Country	Full Name	Reported Affiliation
Eastern Mediterranean Region	Occupied Palestinian Territory, including east Jerusalem	Salfiti, Suha	Ministry of Health
Eastern Mediterranean Region	Occupied Palestinian Territory, including east Jerusalem	Samaro, Ekhlas	Ministry of Health
Eastern Mediterranean Region	Occupied Palestinian Territory, including east Jerusalem	Sawalmeh, Orwah	Ministry of Health
Eastern Mediterranean Region	Oman	Alasfoor, Deena	AlAsfoor Consulting
Eastern Mediterranean Region	Oman	Al Moti, Ali	Ministry of Health
Eastern Mediterranean Region	Oman	Al-Adawi, Suhaila	Ministry of Health
Eastern Mediterranean Region	Oman	Albalushi, Nadheer	Ministry of Health
Eastern Mediterranean Region	Pakistan	Ullah, Aman	Drug Regulatory Authority of Pakistan
Eastern Mediterranean Region	Saudi Arabia	Al Hussain, Fatimah	Food and Drug Authority
Eastern Mediterranean Region	Saudi Arabia	Alhatareshah, Abdullah	Food and Drug Authority
Eastern Mediterranean Region	Saudi Arabia	Al-Owairdhi, Mohammad	Saudi Food and Drug Authority
Eastern Mediterranean Region	Sudan	Khalid, Nahid Idris	World Health Organization (WHO)
Eastern Mediterranean Region	Syrian Arab Republic	Barrou, Sawsan	Ministry of Health
Eastern Mediterranean Region	Syrian Arab Republic	Sallouta, Razan	Ministry of Health
Eastern Mediterranean Region	Syrian Arab Republic	Zghaibeh, Hala	World Health Organization (WHO)
Eastern Mediterranean Region	Tunisia	Jameleddine, Mouna	National Authority for Assessment and Accreditation in Healthcare
Eastern Mediterranean Region	Tunisia	Dahmani, Hajer	National Laboratory of Control of Medicines, Aix Marseille University
Eastern Mediterranean Region	Tunisia	Saksena, Priyanka	World Health Organization (WHO)
Eastern Mediterranean Region	United Arab Emirates	Al Bastaki, Ruqaya	Ministry of Health and Prevention
Eastern Mediterranean Region	United Arab Emirates	Al-Memari, Sumaya	Ministry of Health and Prevention
Eastern Mediterranean Region	United Arab Emirates	Elshamy, Amin	Ministry of Health and Prevention
Eastern Mediterranean Region	Yemen	Hubaishi, Suaad	Supreme Board of Drugs and Medical Appliances
European Region	Albania	Rustemi, Florjana	Health Insurance Fund
European Region	Albania	Picari, Ledina	Ministry of Health and Social Protection
European Region	Albania	Ceci, Ranela	National Agency for Medicinal Products and Medical Devices
European Region	Armenia	Ghazaryan, Lilit	Scientific Centre of Drug and Medical Technology Expertise

WHO Region	Reported Country	Full Name	Reported Affiliation
European Region	Austria	Zimmermann, Nina	Austrian National Public Health Institute
European Region	Austria	Eichwalder, Stefan	Federal Ministry of Health
European Region	Austria	Vogler, Sabine	Gesundheit Österreich GmbH (GÖG / (Austrian National Public Health Institute))
European Region	Austria	Iskra, Simona	Ministry of Health
European Region	Austria	Ventura, Ilana	Ministry of Health
European Region	Azerbaijan	Badalov, Matin	Ministry of Economy of the Azerbaijan Republic
European Region	Azerbaijan	Azizbayov, Parviz	Ministry of Health
European Region	Azerbaijan	Gurbanov, Hamid	Ministry of Health
European Region	Azerbaijan	Hasanov, Farid	Ministry of Health
European Region	Belgium	Nia, Ana	Acumen Public Affairs
European Region	Belgium	Abdelall, Linda	Association of European Cancer Leagues (ECL)
European Region	Belgium	Yared, Wendy	Association of European Cancer Leagues (ECL)
European Region	Belgium	Florinis, Dimitrios	European Commission
European Region	Belgium	Geslin, Laure	European Commission
European Region	Belgium	Peers, Kristine	European Federation of Pharmaceutical Industries Associations
European Region	Belgium	Panteli, Dimitra	European Observatory on Health Systems and Policies
European Region	Belgium	Immonen, Kaisa	European Patients' Forum
European Region	Belgium	Kasilingam, Elisabeth	European Patients' Forum
European Region	Belgium	Natsis, Yannis	European Public Health Alliance
European Region	Belgium	Rodzinka, Marcin	Global Health Advocates
European Region	Belgium	Kanga-Tona, Thomas	International Association of Mutual Benefit Societies
European Region	Belgium	Rommel, Ward	Kom op tegen Kanker
European Region	Belgium	Deborggraeve, Stijn	Médecins Sans Frontières (MSF)
European Region	Belgium	Piedade, Diogo	Medicines for Europe / International Generic and Biosimilar Medicines Association (IGBA)
European Region	Belgium	Sercic, Maja	Medicines for Europe / International Generic and Biosimilar Medicines Association (IGBA)
European Region	Belgium	Van Den Hoven, Adrian	Medicines for Europe / International Generic and Biosimilar Medicines Association (IGBA)
European Region	Belgium	Arickx, Francis	National Institute for Health and Disability Insurance (INAMI-RIZIV), Belgium
European Region	Belgium	Gurnet, Nathan	National Institute for Health and Disability Insurance (INAMI-RIZIV), Belgium
European Region	Belgium	Kleinermans, Diane	National Institute for Health and Disability Insurance (INAMI-RIZIV), Belgium
European Region	Belgium	Mutemberezi, Valentin	National Institute for Health and Disability Insurance (INAMI-RIZIV), Belgium
European Region	Belgium	Nauwelaerts, Evelien	National Institute for Health and Disability Insurance (INAMI-RIZIV), Belgium
European Region	Belgium	Sonemann, Anja	National Institute for Health and Disability Insurance (INAMI-RIZIV), Belgium
European Region	Belgium	Van De Vijver, Inneke	National Institute for Health and Disability Insurance (INAMI-RIZIV), Belgium
European Region	Belgium	Hendrickx, Anne	Union Nationale des Mutualités Socialistes - Solidaris

WHO Region	Reported Country	Full Name	Reported Affiliation
European Region	Bulgaria	Danchev, Nikolai	National Council on Prices and Reimbursement of Medicinal Products
European Region	Croatia	Mihalic, Vladimir	Agency for Medicinal Products and Medical Devices
European Region	Croatia	Matuzović, Jelena	Croatian Health Insurance Fund
European Region	Croatia	Bogut Baric, Martina	Ministry of Health
European Region	Cyprus	Petrou, Panagiotis	University of Nicosia
European Region	Czechia	Karaskova, Eva	Ministry of Health
European Region	Czechia	Fuksa, Leos	State Institute for Drug Control
European Region	Czechia	Vocelka, Milan	State Institute for Drug Control
European Region	Denmark	Behnk, Trine	Amgros I/S
European Region	Denmark	Lauritzen, Diana	Danish Medicines Agency
European Region	Denmark	Madsen, Kim	Danish Medicines Agency
European Region	Denmark	Syberg Hazelton, Rasmus	Ministry of Health
European Region	Denmark	Tordrup, David	Triangulate Health Ltd / WHO Collaborating Centre for Pharmaceutical Policy and Regulation
European Region	Denmark	Bak Pedersen, Hanne	UNICEF Supply Division
European Region	Denmark	Fourati, Akthem	UNICEF Supply Division
European Region	Denmark	Kalpaxis, Philipp	UNICEF Supply Division
European Region	Denmark	Mutuerandu, David	Vaccine Centre, UNICEF Supply Divison
European Region	Denmark	Azzopardi Muscat, Natasha	World Health Organization (WHO)
European Region	Denmark	Corbex, Marilys	World Health Organization (WHO)
European Region	Denmark	Garner, Sarah	World Health Organization (WHO)
European Region	Denmark	Humbert, Tifenn	World Health Organization (WHO)
European Region	Denmark	Permanand, Govin	World Health Organization (WHO)
European Region	Denmark	Pirgari, Dorina	World Health Organization (WHO)
European Region	Estonia	Veliste, Kärt	Estonian Health Insurance Fund
European Region	Estonia	Eespere, Katri	Ministry of Social Affairs
European Region	Estonia	Lopato, Eda	Ministry of Social Affairs
European Region	France	Lambert, Aurore	Agence Française de Développement
European Region	France	Seydoux, Stéphanie	Not applicable
European Region	France	Rique, Jeanne	French Ministry for Europe and Foreign Affairs
European Region	France	Paris, Valérie	Haute Autorité de Santé (HAS)
European Region	France	Veras, Juliana	Médecins du Monde
European Region	France	Ernoul, Nathalie	Médecins Sans Frontières (MSF) Access Campaign
European Region	France	Albert, Sophie	Ministry of Europe and Foreign Affairs
European Region	France	Londeix, Pauline	Observatoire Transparence Médicaments
European Region	France	Martin, Jerome	Observatoire Transparence Médicaments
European Region	France	Barrenho, Eliana	Organisation for Economic Co-operation and Development (OECD)
European Region	France	Capobianco, Antonio	Organisation for Economic Co-operation and Development (OECD)
European Region	France	Dedet, Guillaume	Organisation for Economic Co-operation and Development (OECD)
European Region	France	Wenzl, Martin	Organisation for Economic Co-operation and Development (OECD)

WHO Region	Reported Country	Full Name	Reported Affiliation
European Region	France	Manti, Martial	Sanofi
European Region	France	Fihman, Johanna	World Health Organization (WHO)
European Region	France	Guillot, Patricia	World Health Organization (WHO)
European Region	France	Rodrigues, Jonathan	World Health Organization (WHO)
European Region	France	Tisocki, Klara	World Health Organization (WHO)
European Region	France	Trochez, Claire	World Health Organization (WHO)
European Region	Germany	Koppe, Cordelia	IKK e.V. - Joint Representation of Guild Health Insurance Funds
European Region	Germany	Viciano, Astrid	Süddeutsche Zeitung
European Region	Germany	Webb, Erin	Technical University of Berlin
European Region	Germany	Huwald, Robin	University Bremen
European Region	Greece	Petelos, Elena	CSFM, Department of Social Medicine, School of Medicine
European Region	Greece	Lingri, Dimitra	Supreme Court-EOPYY, Greece
European Region	Hungary	Németh, Gergely	National Institute of Health Insurance Fund Management (NEAK)
European Region	Hungary	Merész, Gergő	National Institute of Pharmacy and Nutrition
European Region	Hungary	Szilvia, Bokros	National Institute of Pharmacy and Nutrition
European Region	Hungary	Szloboda, Csandra	National Institute of Pharmacy and Nutrition
European Region	Hungary	Bányai, Eszter	National Institute of Pharmacy and Nutrition (OGYÉI)
European Region	Hungary	Egervári, Adrienn	National Institute of Pharmacy and Nutrition (OGYÉI)
European Region	Italy	Magrini, Nicola	Agenzia Italiana del Farmaco
European Region	Italy	Roffiaen, Charlotte	France Assos Santé
European Region	Italy	Arnaudo, Luca	Italian Medicines Agency (AIFA)
European Region	Italy	Carletto, Angelica	Italian Medicines Agency (AIFA)
European Region	Italy	Russo, Pierluigi	Italian Medicines Agency (AIFA)
European Region	Italy	Traversa, Giuseppe	Italian Medicines Agency (AIFA)
European Region	Italy	Ribolzi, Francesco	World Health Organization (WHO)
European Region	Kazakhstan	Kostyuk, Alexander	Kazakh Association of HTA, EBM & HEOR
European Region	Kazakhstan	Sembayeva, Bakyt	National Center for Expertise of Medicines and Medical Devices
European Region	Kazakhstan	Yevich, Vladimir	National Center for Expertise of Medicines and Medical Devices
European Region	Kazakhstan	Zhanatbekova, Assel	National Center for Expertise of Medicines and Medical Devices
European Region	Kyrgyzstan	Ismailov, Isabek	Department of Medicines and Medical Devices
European Region	Kyrgyzstan	Bolotbekova, Akzholtoi	Ministry of Health and Social Development
European Region	Kyrgyzstan	Sulaimanova, Aisha	Ministry of Health and Social Development
European Region	Kyrgyzstan	Turdaliev, Asel	Ministry of Health and Social Development
European Region	Kyrgyzstan	Moldoisaeva, Saltanat	World Health Organization (WHO)
European Region	Lithuania	Mačinskas, Justas	Ministry of Health
European Region	Lithuania	Meldziukaite, Vilma	Ministry of Health
European Region	Lithuania	Oraitė, Anželika	Ministry of Health
European Region	Malta	Anastasi, Alison	Central Procurement and Supplies Unit
European Region	Malta	Formosa, Antonia	Directorate Pharmaceutical Affairs
European Region	Malta	Magrin Sammut, Sylvana	Directorate Pharmaceutical Affairs

WHO Region	Reported Country	Full Name	Reported Affiliation
European Region	Malta	Serracino Inglott, Anthony	Ministry of Health
European Region	Netherlands	Iyer, Jayasree	Access to Medicine Foundation
European Region	Netherlands	Martinez, Claudia	Access to Medicine Index
European Region	Netherlands	Van Waalwijk Van Doorn-Khosrovani, Sahar	CZ Health Insurance
European Region	Netherlands	Muller, Guy	Dutch Cancer Society - European Fair Pricing Network
European Region	Netherlands	Akoum, Sizar	Freelance
European Region	Netherlands	Vidal, Jaume	Health Action International (HAI)
European Region	Netherlands	Ruttenberg, Leontien	Imres B.V.
European Region	Netherlands	't Hoen, Elisabeth	Medicines Law & Policy
European Region	Netherlands	Van Den Berg, Seriana	Ministry of Health, Welfare and Sport
European Region	Netherlands	Van Raaij, Marcel	Ministry of Health, Welfare and Sport
European Region	Netherlands	Franzen, Nora	Netherland Cancer Insitute
European Region	Netherlands	Lopert, Ruth	Organisation for Economic Co-operation and Development
European Region	Netherlands	Dunselman, Astrid	Permanent Mission of the Kingdom of the Netherlands
European Region	Netherlands	Bannenberg, Wilbert	Pharmaceutical Accountability Foundation
European Region	Netherlands	Voogd, Sabina	Pharmaceutical Accountability Foundation
European Region	Netherlands	Ewen, Marg	Stichting Health Action International
European Region	Netherlands	De Vries, Elisabeth	University Medical Center Groningen
European Region	Netherlands	Mantel-Teeuwisse, Aukje	Utrecht Centre of Pharmaceutical Policy and Regulation
European Region	Netherlands	Joosse, Iris	Utrecht University
European Region	Netherlands	Van Den Ham, Rianne	Utrecht University
European Region	Norway	Festøy, Helga	Norwegian Medicines Agency
European Region	Norway	Hågå, Audun	Norwegian Medicines Agency
European Region	Norway	Sanne, Arne-Petter	Norwegian Medicines Agency
European Region	Norway	Larsen, Bjørn-Inge	Norwegian Ministry of Health and Social Care Services
European Region	Portugal	Duarte, Guilherme	Ministry of Foreign Affairs
European Region	Portugal	Furtado, Claudia	Portuguese National Authority of Medicines and Health Products (INFARMED)
European Region	Portugal	Santos Ivo, Rui	Portuguese National Authority of Medicines and Health Products (INFARMED)
European Region	Republic of Moldova	Jeleznii, Gabriela	Compania Națională de Asigurări în Medicină
European Region	Republic of Moldova	Gorceag, Gheorghe	Ministry of Health, Labour and Social Protection
European Region	Republic of Moldova	Barba, Adrian	National Health Insurance Company
European Region	Republic of Moldova	Chitan, Elena	National Health Insurance Company
European Region	Republic of Moldova	Bezverhni, Zinaida	World Health Organization (WHO)
European Region	Russian Federation	Binko, Konstantin	Ministry of Health
European Region	Russian Federation	Efimova, Elena	Ministry of Health
European Region	Russian Federation	Yakubov, Ruslan	Ministry of Health
European Region	Slovenia	Radulovic, Momir	Agency for Medicinal Products and Medical Devices

WHO Region	Reported Country	Full Name	Reported Affiliation
European Region	Slovenia	Mikolic, Jure	Health Insurance Institute of Slovenia
European Region	Spain	Blanqué, Nerea	Alira health
European Region	Spain	Gutiérrez-Ibarluzea, Iñaki	EuroScan/iHTS Network
European Region	Spain	Guiu Segura, Josep Maria	Federal Ministry of Health
European Region	Spain	Gilardino, Ramiro	HE-Xperts Consulting LLC
European Region	Spain	Meirovich, Claudio	World Health Organization (WHO)
European Region	Spain	Redini Blumenthal, Ivan	World Health Organization (WHO)
European Region	Spain	Villanueva Olivo, Elena	World Health Organization (WHO)
European Region	Switzerland	Weerasuriya, Krisantha	Consultant
European Region	Switzerland	Lazdins, Janis	Council on Health Research for Development
European Region	Switzerland	Childs, Michelle	Drugs for Neglected Diseases initiative (DNDi)
European Region	Switzerland	Vyas, Malvika	European Society for Medical Oncology (ESMO)
European Region	Switzerland	Lashley-Johnson, Deborah	Executive Office of the President, Office of the U.S. Trade Representative
European Region	Switzerland	Indermitte, Jörg	Federals Office of Public Health
European Region	Switzerland	Kronig Romero, Nora	Federals Office of Public Health
European Region	Switzerland	Schwab, Martina	Federals Office of Public Health
European Region	Switzerland	Vetter, Beatrice	Foundation for Innovative New Diagnostics (FIND)
European Region	Switzerland	Torreele, Els	Freelance
European Region	Switzerland	Waning, Brenda	Global Drug Facility, Stop TB Partnership at UNOPS
European Region	Switzerland	Moon, Suerie	Global Health Centre, Graduate Institute of Geneva
European Region	Switzerland	Sachse, Tatjana	Global Medical Technology Alliance / Sidley Austin
European Region	Switzerland	Alonso Ruiz, Adrián	Graduate Institute Geneva
European Region	Switzerland	Amini, Sara	International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
European Region	Switzerland	Cueni, Thomas	International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
European Region	Switzerland	Jones, Abigail	International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
European Region	Switzerland	Kalha, Komal	International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
European Region	Switzerland	Kox, Suzette	International Generic and Biosimilar Medicines Association (IGBA)
European Region	Switzerland	Balasubramaniam, Thiru	Knowledge Ecology International (KEI)
European Region	Switzerland	Passaggio, Luca	LP Medical Consulting Sagl
European Region	Switzerland	Cepuch, Christa	Médecins Sans Frontières (MSF)
European Region	Switzerland	Hu, Yuanqiong	Médecins Sans Frontières (MSF)
European Region	Switzerland	Mara, Kaitlin	Medicines Law & Policy
European Region	Switzerland	Burrone, Esteban	Medicines Patent Pool (MPP)
European Region	Switzerland	Gore, Charles	Medicines Patent Pool (MPP)
European Region	Switzerland	Maistat, Mila	Medicines Patent Pool (MPP)



WHO Region	Reported Country	Full Name	Reported Affiliation
European Region	Switzerland	Roediger, Alexander	Merck
European Region	Switzerland	Briquet Mosalo, Marion	Ministry for Europe and Foreign Affairs
European Region	Switzerland	Mestrinaro, Michele	Novartis
European Region	Switzerland	Durisch, Patrick	Public Eye
European Region	Switzerland	Imhof, René	Roche
European Region	Switzerland	Oberreiter, Michael	Roche
European Region	Switzerland	Puri, Monika	Roche
European Region	Switzerland	María Correa, Carlos	South Centre
European Region	Switzerland	Munoz Tellez, Viviana	South Centre
European Region	Switzerland	Syam, Nirmalya	South Centre
European Region	Switzerland	Kohler, Dimitri	Swiss Cancer League
European Region	Switzerland	Sato, Takanori	Takeda Pharmaceutical Company
European Region	Switzerland	Jayasekar Zurn, Shalini	Union for International Cancer Control
European Region	Switzerland	Duneton, Philippe	UNITAID
European Region	Switzerland	Levy, Marie	UNITAID
European Region	Switzerland	Osigbesan, Ademola	UNITAID
European Region	Switzerland	Timmermans, Karin	UNITAID
European Region	Switzerland	Vokinger, Kerstin	University of Zurich
European Region	Switzerland	Bagozzi, Daniela	World Health Organization (WHO)
European Region	Switzerland	Beyer, Peter	World Health Organization (WHO)
European Region	Switzerland	Cappello, Bernadette	World Health Organization (WHO)
European Region	Switzerland	Cernuschi, Tania	World Health Organization (WHO)
European Region	Switzerland	Chadwick, Chris	World Health Organization (WHO)
European Region	Switzerland	Colbert, Allison	World Health Organization (WHO)
European Region	Switzerland	Cruz, Meyali	World Health Organization (WHO)
European Region	Switzerland	Dimancesco, Deirdre	World Health Organization (WHO)
European Region	Switzerland	Dong, Jicui	World Health Organization (WHO)
European Region	Switzerland	Dueñas, Erika	World Health Organization (WHO)
European Region	Switzerland	Enoos, Bashier	World Health Organization (WHO)
European Region	Switzerland	Esquivel, Christopher	World Health Organization (WHO)
European Region	Switzerland	Estevao Cordeiro, Steve	World Health Organization (WHO)
European Region	Switzerland	Homb, Nicole	World Health Organization (WHO)
European Region	Switzerland	Huttner, Benedikt	World Health Organization (WHO)
European Region	Switzerland	Ivanovska, Verica	World Health Organization (WHO)
European Region	Switzerland	Iyengar, Swathi	World Health Organization (WHO)
European Region	Switzerland	Jorgensen, Tine	World Health Organization (WHO)
European Region	Switzerland	Kotur Corliss, Sandra	World Health Organization (WHO)
European Region	Switzerland	Lee, Diana	World Health Organization (WHO)
European Region	Switzerland	Matheu, Jorge	World Health Organization (WHO)
European Region	Switzerland	Miyazaki-Krause, Ryoko	World Health Organization (WHO)
European Region	Switzerland	Ondari, Clive	World Health Organization (WHO)

WHO Region	Reported Country	Full Name	Reported Affiliation
European Region	Switzerland	Rodriguez, Daniela	World Health Organization (WHO)
European Region	Switzerland	Sands, Anita	World Health Organization (WHO)
European Region	Switzerland	Sidatt, Hassene	World Health Organization (WHO)
European Region	Switzerland	Simão, Mariângela	World Health Organization (WHO)
European Region	Switzerland	Tay-Teo, Kiu	World Health Organization (WHO)
European Region	Switzerland	Velazquez Berumen, Adriana	World Health Organization (WHO)
European Region	Switzerland	Xu, Hongyi	World Health Organization (WHO)
European Region	Switzerland	Bartels, Hans Georg	World Intellectual Property Organization (WIPO)
European Region	Switzerland	Miyamoto, Tomoko	World Intellectual Property Organization (WIPO)
European Region	Switzerland	Zhao, Zhao	World Intellectual Property Organization (WIPO)
European Region	Switzerland	Kampf, Roger	World Trade Organization (WTO)
European Region	Switzerland	Khazin, Bassam	World Trade Organization (WTO)
European Region	Switzerland	Mccann, Maegan	World Trade Organization (WTO)
European Region	Switzerland	Taubman, Antony	World Trade Organization (WTO)
European Region	Switzerland	Wu, Xiaoping	World Trade Organization (WTO)
European Region	Switzerland	Muhunde, Alain Claude	Yolse, Santé Publique et Innovation
European Region	Switzerland	Simporé, Safiatou	Yolse, Santé Publique et Innovation
European Region	Tajikistan	Kalandarova, Nargis	Service of State Surveillance of Health and Social Protection of Population
European Region	Turkey	Aylak Ayas, Selda	Turkish Medicines and Medical Devices Agency
European Region	Turkey	Bayar, Banu	Turkish Medicines and Medical Devices Agency
European Region	Turkey	Nacar, Seray	Turkish Medicines and Medical Devices Agency
European Region	Ukraine	Kharchenko, Tetiana	Medical Procurement of Ukraine
European Region	Ukraine	Morozova, Mariia	Medical Procurement of Ukraine
European Region	Ukraine	Babenko, Mykhaylo	Ministry of Health
European Region	Ukraine	Lobas, Mykhaylo	Ministry of Health
European Region	Ukraine	Pazerska, Tetiana	Ministry of Health
European Region	Ukraine	Piniazhko, Oresta	Ministry of Health
European Region	Ukraine	Pakhnutova, Svitlana	World Health Organization (WHO)
European Region	United Kingdom of Great Britain and Northern Ireland	Torbett, Richard	Association of the British Pharmaceutical Industry/International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
European Region	United Kingdom of Great Britain and Northern Ireland	Wheatley, Emma	Coalition for Epidemic Preparedness Innovations (CEPI)
European Region	United Kingdom of Great Britain and Northern Ireland	Giuliani, Rosa	European Society for Medical Oncology (ESMO)
European Region	United Kingdom of Great Britain and Northern Ireland	Gray, Holly	Foreign, Commonwealth and Development Office
European Region	United Kingdom of Great Britain and Northern Ireland	Turkoglu, Bahar	Gilead Sciences
European Region	United Kingdom of Great Britain and Northern Ireland	Anderson, James	International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

WHO Region	Reported Country	Full Name	Reported Affiliation
European Region	United Kingdom of Great Britain and Northern Ireland	Tafazzoli, Meena	International Working Group for Health Systems Strengthening
European Region	United Kingdom of Great Britain and Northern Ireland	Klatman, Emma	Life for a Child
European Region	United Kingdom of Great Britain and Northern Ireland	Ivama Brummell, Adriana	London School of Economics and Political Science (LSE)
European Region	United Kingdom of Great Britain and Northern Ireland	Naci, Huseyin	London School of Economics and Political Science (LSE)
European Region	United Kingdom of Great Britain and Northern Ireland	Richardson, Erica	London School of Hygiene and Tropical Medicine (LSHTM)
European Region	United Kingdom of Great Britain and Northern Ireland	Scourse, Roz	MSF Access Campaign
European Region	United Kingdom of Great Britain and Northern Ireland	Pencheva, Rositsa	Rositsa Pencheva
European Region	United Kingdom of Great Britain and Northern Ireland	Fitzpatrick, Saoirse	STOPAIDS
European Region	United Kingdom of Great Britain and Northern Ireland	Shashikant, Sangeeta	Third World Network
European Region	United Kingdom of Great Britain and Northern Ireland	Mazzucato, Marianna	University College London
European Region	United Kingdom of Great Britain and Northern Ireland	Li, Henry	University College London Institute for Innovation and Public Purpose
European Region	United Kingdom of Great Britain and Northern Ireland	Gohil, Sapna	University Hospitals Coventry & Warwickshire NHS Trust
European Region	United Kingdom of Great Britain and Northern Ireland	Ding, Jin	University of Sheffield
European Region	United Kingdom of Great Britain and Northern Ireland	Martin, Paul	University of Sheffield
European Region	United Kingdom of Great Britain and Northern Ireland	Claxton, Karl	University of York
European Region	United Kingdom of Great Britain and Northern Ireland	Clarke, Brandon	Wellcome Trust
European Region	United Kingdom of Great Britain and Northern Ireland	Hore, Rachael	Wellcome Trust
European Region	United Kingdom of Great Britain and Northern Ireland	Whiting, Ed	Wellcome Trust
European Region	United Kingdom of Great Britain and Northern Ireland	Barber, Melissa	World Health Organization (WHO)
European Region	United Kingdom of Great Britain and Northern Ireland	Harris, Rachelle	World Health Organization (WHO)
European Region	Uzbekistan	Nartaev, Agzam	Agency on Development of Pharmaceutical Industry, Ministry of Health of the Republic of Uzbekistan
Region of the Americas	Argentina	Flores Lazdin, Carolina	Bayer
Region of the Americas	Argentina	Escobar, Carlos	Cámara Argentina de Especialidades Medicinales (CAEME)
Region of the Americas	Argentina	Giannoni, Fernando	Cámara Argentina de Especialidades Medicinales (CAEME)
Region of the Americas	Argentina	Claverí, Mauricio	Cámara Industrial de Laboratorios Farmacéuticos Argentinos
Region of the Americas	Argentina	Maito, Miguel	Cámara Industrial de Laboratorios Farmacéuticos Argentinos

WHO Region	Reported Country	Full Name	Reported Affiliation
Region of the Americas	Argentina	Martinez Diaz, Adriana	Cámara Industrial de Laboratorios Farmacéuticos Argentinos
Region of the Americas	Argentina	Marin, Gustavo	CUFAR Collaborating Center - National University of La Plata - CONICET
Region of the Americas	Argentina	Garcia, Dario	Federación Latinoamericana de Medicina de Emergencias (FLAME)
Region of the Americas	Argentina	Varela, Julia	Fundación GEP
Region of the Americas	Argentina	Di Bello, José	Fundación Grupo Efecto Positivo
Region of the Americas	Argentina	Silvestrini Viola, Constanza	Fundación QUANT
Region of the Americas	Argentina	Pichon-Riviere, Andres	Instituto de Efectividad Clínica y Sanitaria (IECS - Argentina)
Region of the Americas	Argentina	Hasdeu, Santiago	La Red Argentina pública de Evaluación de Tecnologías Sanitarias (RedArets)
Region of the Americas	Argentina	Casal, Leandro	Merck
Region of the Americas	Argentina	Pianezza, Ana	Ministry of Foreign Affairs, International Trade and Worship
Region of the Americas	Argentina	Alvarez, Jorgelina	Ministry of Health
Region of the Americas	Argentina	Benchetrit, Silvina	Ministry of Health
Region of the Americas	Argentina	De La Puente, Catalina	Ministry of Health
Region of the Americas	Argentina	Gallardo, Patricia	Ministry of Health
Region of the Americas	Argentina	Grigioni, Georgina	Ministry of Health
Region of the Americas	Argentina	Ignacio Correa, Juan	Ministry of Health
Region of the Americas	Argentina	Iusef Venturini, Nasim	Ministry of Health
Region of the Americas	Argentina	Melero, Emiliano	Ministry of Health
Region of the Americas	Argentina	Messina, Natalia	Ministry of Health
Region of the Americas	Argentina	Moretti, Carla	Ministry of Health
Region of the Americas	Argentina	Musetti, Carola	Ministry of Health
Region of the Americas	Argentina	Palopoli, Gastón	Ministry of Health
Region of the Americas	Argentina	Ponsa, Eugenia	Ministry of Health
Region of the Americas	Argentina	Ramirez, Gabriela	Ministry of Health
Region of the Americas	Argentina	Tarragona, Sonia	Ministry of Health
Region of the Americas	Argentina	Valentini, Pia	Ministry of Health

WHO Region	Reported Country	Full Name	Reported Affiliation
Region of the Americas	Argentina	Vizzotti, Carla	Ministry of Health
Region of the Americas	Argentina	Torales, Santiago	National Commission for Health Technologies Assessment (CONETEC)
Region of the Americas	Argentina	Luque, Paula	Novartis
Region of the Americas	Argentina	Aizenberg, Marisa	Observatory on the Right to Health, Universidad de Buenos Aires
Region of the Americas	Argentina	Ané, Bruno	Permanent Mission of Argentina to UN
Region of the Americas	Argentina	Rosales, Carlos	Permanent Mission of Argentina to UN
Region of the Americas	Argentina	Schiaffino, María Jimena	Permanent Mission of Argentina to UN
Region of the Americas	Argentina	Villegas, Federico	Permanent Mission of Argentina to UN
Region of the Americas	Argentina	Romano, Ignacio	Pfizer
Region of the Americas	Argentina	Di Giano, María Lorena	RedLAM (Latin American Network for Access to Medicines)
Region of the Americas	Argentina	Bracamonte, Silvina Andrea	The Federal National Civil and Commercial Court No. 1 (Argentina)
Region of the Americas	Argentina	Cassinerio, José Luis	The Federal National Civil and Commercial Court No. 4 (Argentina)
Region of the Americas	Argentina	Lamfre, Laura	Universidad Nacional del Comahue
Region of the Americas	Argentina	Balbi, Laura	World Health Organization (WHO)
Region of the Americas	Argentina	Contreras, Gonzalo	World Health Organization (WHO)
Region of the Americas	Argentina	Hallar, Kemel	World Health Organization (WHO)
Region of the Americas	Argentina	Marzoa, Cecilia	World Health Organization (WHO)
Region of the Americas	Argentina	Pérez-Gutiérrez, Enrique	World Health Organization (WHO)
Region of the Americas	Argentina	Uribe, Javier	World Health Organization (WHO)
Region of the Americas	Barbados	Sagastuy, Begoña	World Health Organization (WHO)
Region of the Americas	Bermuda	Brathwaite, Ricky	Bermuda Health Council
Region of the Americas	Bolivia (Plurinational State of)	Caceres, Julio	Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED)
Region of the Americas	Bolivia (Plurinational State of)	Sanchez Callisaya, Jannet	Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED)
Region of the Americas	Bolivia (Plurinational State of)	Saucedo Salas, Angel	Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED)
Region of the Americas	Bolivia (Plurinational State of)	Saravia, Felipe	World Health Organization (WHO)
Region of the Americas	Brazil	Contó, Murilo	Boston Scientific

WHO Region	Reported Country	Full Name	Reported Affiliation
Region of the Americas	Brazil	Garcia, Gustavo	Brazilian Health Regulatory Agency (ANVISA)
Region of the Americas	Brazil	Jourdan, Cristiane	Brazilian Health Regulatory Agency (ANVISA)
Region of the Americas	Brazil	Lopes, Rodrigo	Brazilian Health Regulatory Agency (ANVISA)
Region of the Americas	Brazil	Rêgo, Fernando	Brazilian Health Regulatory Agency (ANVISA)
Region of the Americas	Brazil	Vidal, Julia	Brazilian Health Regulatory Agency (ANVISA)
Region of the Americas	Brazil	Canuto, Vânia	Department of Management and Incorporation of Technologies in Health (DGITS)
Region of the Americas	Brazil	Viegas, Francisco	Drugs for Neglected Diseases Initiative (DNDi)
Region of the Americas	Brazil	Bermudez, Jorge	Escola Nacional de Saúde Pública, FIOCRUZ
Region of the Americas	Brazil	Safatle, Leandro	Fiocruz
Region of the Americas	Brazil	Villard, Pedro	Grupo de Trabalho sobre Propriedade Intelectual (GTPI)
Region of the Americas	Brazil	Ortiz, Juliana	Independent
Region of the Americas	Brazil	Carolina Navarrete, Ana	Instituto Brasileiro de Defesa do Consumidor (Brazilian Institute for Consumer Protection)
Region of the Americas	Brazil	Santos, Marisa	Instituto Nacional de Cardiologia (INC)
Region of the Americas	Brazil	Nobrega, Marjorie	Janssen
Region of the Americas	Brazil	Alexandre, Cristina	Ministry of Health
Region of the Americas	Brazil	Bonan, Luciene	Ministry of Health
Region of the Americas	Brazil	De Lima, Alexandre	Ministry of Health
Region of the Americas	Brazil	Louly, Priscila	Ministry of Health
Region of the Americas	Brazil	Ribeiro, Alane	Ministry of Health
Region of the Americas	Brazil	Pontes, Marcela	Ministry of Health of Brazil
Region of the Americas	Brazil	Mendonça, Lethícia	Ministry of Justice and Public Security
Region of the Americas	Brazil	Loze, Priscilla	Roche
Region of the Americas	Brazil	Souza, Kathiaja Miranda	World Health Organization (WHO)
Region of the Americas	Brazil	Veloso, Natália	World Health Organization (WHO)
Region of the Americas	Canada	Fulton, John R.	BioNiagara
Region of the Americas	Canada	Gagnon, Marc-Andre	Carleton University

WHO Region	Reported Country	Full Name	Reported Affiliation
Region of the Americas	Canada	Herder, Matthew	Dalhousie University
Region of the Americas	Canada	Birks, Katie	Global Affairs Canada
Region of the Americas	Canada	Mullally, Shauna	Global Clinical Engineering Alliance
Region of the Americas	Canada	Prada, Gabriela	Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA)
Region of the Americas	Canada	Kah, Anna	Government of Northwest Territories
Region of the Americas	Canada	Cheung, Lawrence	Health Canada
Region of the Americas	Canada	Elliott, Richard	HIV Legal Network
Region of the Americas	Canada	Schouten, Arianna	Knowledge Ecology International (KEI)
Region of the Americas	Canada	Clark, Douglas	Patented Medicine Prices Review Board
Region of the Americas	Canada	Menzies, Jeffrey	Patented Medicine Prices Review Board
Region of the Americas	Canada	Potashnik, Tanya	Pmprb
Region of the Americas	Canada	Morgan, Steve	University of British Columbia
Region of the Americas	Canada	Kohler, Jillian	University of Toronto
Region of the Americas	Canada	Aarsand, Rebekka	World Health Organization (WHO)
Region of the Americas	Chile	Garces, Elias	Cenabast
Region of the Americas	Chile	Villarroel, Luis	Corporacion Innovarte
Region of the Americas	Chile	De La Puente, Catherine	Ministry of Health
Region of the Americas	Chile	Poblete, Sergio	Ministry of Health
Region of the Americas	Colombia	Cuartas, José	Constitutional Court of Colombia
Region of the Americas	Colombia	Rossi, Francisco	Fundación IFARMA
Region of the Americas	Colombia	Vargas-Pelaez, Claudia Marcela	Fundación IFARMA
Region of the Americas	Colombia	Vasquez, Mayra	National Agency for Healthcare Providers
Region of the Americas	Colombia	Mendoza, Laura	Takeda Pharmaceutical Company
Region of the Americas	Colombia	Mendieta, Luisa	Universidad Nacional de Colombia
Region of the Americas	Colombia	Peña, Ricardo	Universidad Nacional de Colombia
Region of the Americas	Colombia	Zapata Velásquez, Juan	Universidad Nacional de Colombia

WHO Region	Reported Country	Full Name	Reported Affiliation
Region of the Americas	Colombia	Andia, Tatiana	University of the Andes, Colombia
Region of the Americas	Costa Rica	Herrera, Ileana	Ministry of Health
Region of the Americas	Costa Rica	Vega Cruz, Xiomara	Ministry of Health
Region of the Americas	Dominican Republic	Díaz Medina, Yesenia	Superintendencia de Salud y Riesgos Laborales
Region of the Americas	Ecuador	Cuenca, Alex	Ministry of Public Health
Region of the Americas	Ecuador	Flores Enríquez, Jaime	Ministry of Public Health
Region of the Americas	Ecuador	Landivar Rosales, Lourdes	Ministry of Public Health
Region of the Americas	El Salvador	Rivera Flores, Luis	Dirección Nacional de Medicamentos
Region of the Americas	El Salvador	Castro, Jaime	Instituto Salvadoreño del Seguro Social
Region of the Americas	El Salvador	Chávez, Ernesto	Instituto Salvadoreño del Seguro Social
Region of the Americas	El Salvador	Ruano Arévalo, Ricardo	Ministry of Health
Region of the Americas	Grenada	Isaac, Camille	Ministry of Health
Region of the Americas	Guatemala	Martínez, Ana	Instituto Guatemalteco de Seguridad Social
Region of the Americas	Guatemala	Archila Figueroa, Jorge	Ministry of Health
Region of the Americas	Guatemala	Cúmes Salazar, Clara	Ministry of Health
Region of the Americas	Guatemala	Gomez, Helder	Ministry of Health
Region of the Americas	Guatemala	Avilés, Manuel Antonio	United Nations Office for Project Services (UNOPS)
Region of the Americas	Haiti	Letelier, Jisette	Direction de la Pharmacie, du Médicament et de la Médecine Traditionnelle
Region of the Americas	Honduras	Nazar, Silvia	Secretaría de Salud
Region of the Americas	Honduras	Giron, Nora	World Health Organization (WHO)
Region of the Americas	Jamaica	Davis, Donovan	Ministry of Health and Wellness
Region of the Americas	Jamaica	Anderson, Everton	National Health Fund
Region of the Americas	Mexico	Ordelin Font, Jorge Luis	Conferencia Interamericana de Seguridad Social
Region of the Americas	Mexico	Camacho, Araceli	Health Secretary
Region of the Americas	Mexico	Calderon, Melina	Johnson & Johnson
Region of the Americas	Mexico	Cantero, Marcos	Secretaría de Salud



WHO Region	Reported Country	Full Name	Reported Affiliation
Region of the Americas	Mexico	Dauphin Llorens, Catherine	UNITAID
Region of the Americas	Nicaragua	Cisneros, Jose	Ministry of Health
Region of the Americas	Nicaragua	Lacayo, Alvaro	Ministry of Health
Region of the Americas	Panama	Escobar, Marta	Mas movil
Region of the Americas	Panama	Castillo, Berenice	Ministry of Health
Region of the Americas	Panama	Credidio, Indira	Ministry of Health
Region of the Americas	Panama	Carrillo Roa, Alejandra	World Health Organization (WHO)
Region of the Americas	Panama	Sagastume, Didia	World Health Organization (WHO)
Region of the Americas	Paraguay	Foth Ferreira, Gabriela	Dirección Nacional de Vigilancia Sanitaria
Region of the Americas	Paraguay	Iliou, Jorge	Dirección Nacional de Vigilancia Sanitaria
Region of the Americas	Peru	Espino, Rocio	Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud
Region of the Americas	Peru	Crisante Nunez, Maruja	Ministry of Health
Region of the Americas	Peru	Medrano Osorio, Aurora	Ministry of Health
Region of the Americas	Peru	Suarez, Dalia	Ministry of Health
Region of the Americas	Peru	Rivas, Pilar	Universidad Peruana Cayetano Heredia
Region of the Americas	Saint Kitts and Nevis	Cranstoun, Gail-I	Ministry of Health
Region of the Americas	Saint Kitts and Nevis	Cranstoun, Kishma	Ministry of Health
Region of the Americas	Saint Lucia	Germaine, Kernel	Ministry of Health, Wellness and the Environment
Region of the Americas	Saint Lucia	Jean, Allison	Ministry of Health, Wellness and the Environment
Region of the Americas	Saint Vincent and the Grenadines	De Shong, Tricia	Ministry of Health, Wellness and the Environment
Region of the Americas	Saint Vincent and the Grenadines	Thomas, Isolin	Ministry of Health, Wellness and the Environment
Region of the Americas	Suriname	Naarendorp, Miriam	Government of Suriname
Region of the Americas	United States of America	Boubeka, Nubert	Ambivium
Region of the Americas	United States of America	Gaugh, David	Association for Accessible Medicines
Region of the Americas	United States of America	Wirtz, Veronika	Boston University School of Public Health
Region of the Americas	United States of America	Van Trieste, Martin	Civica Rx

WHO Region	Reported Country	Full Name	Reported Affiliation
Region of the Americas	United States of America	Blumenthal, David	Commonwealth Fund
Region of the Americas	United States of America	Williams, Reginald	Commonwealth Fund
Region of the Americas	United States of America	Chemali, Nicolas	Eli Lilly
Region of the Americas	United States of America	Docteur, Elizabeth	Elizabeth Docteur Consulting
Region of the Americas	United States of America	Abbott, Frederick	Florida State University College of Law
Region of the Americas	United States of America	Forzley, Michele	Forzley and Associates
Region of the Americas	United States of America	Class, James	Gilead Sciences
Region of the Americas	United States of America	Ives, Ralph	Global Medical Technology Alliance
Region of the Americas	United States of America	Kesselheim, Aaron	Harvard Medical School
Region of the Americas	United States of America	Kashyap, Aruna	Human Rights Watch
Region of the Americas	United States of America	Satterwhite, Erika	International Generic and Biosimilar Medicines Association (IGBA)
Region of the Americas	United States of America	Kong, Alex	Johns Hopkins Bloomberg School of Public Health
Region of the Americas	United States of America	Sharma, Prateek	Johns Hopkins Bloomberg School of Public Health
Region of the Americas	United States of America	So, Anthony	Johns Hopkins Bloomberg School of Public Health
Region of the Americas	United States of America	Woo, Joshua	Johns Hopkins Bloomberg School of Public Health
Region of the Americas	United States of America	Thomas, Adrian	Johnson & Johnson
Region of the Americas	United States of America	Love, James	Knowledge Ecology International
Region of the Americas	United States of America	Gil Abinader, Luis	Knowledge Ecology International (KEI)
Region of the Americas	United States of America	Walkowiak, Helena	Management Sciences for Health
Region of the Americas	United States of America	Hafner, Tamara	Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program
Region of the Americas	United States of America	Salsberg, Corey	Novartis
Region of the Americas	United States of America	Holmes, Patrick	Pfizer
Region of the Americas	United States of America	Munch, Diane	Pfizer
Region of the Americas	United States of America	Rizvi, Zain	Public Citizen
Region of the Americas	United States of America	Brown, Dana	The Democracy Collaborative
Region of the Americas	United States of America	Rius Sanjuan, Judit	United Nations Development Programme (UNDP)

WHO Region	Reported Country	Full Name	Reported Affiliation
Region of the Americas	United States of America	Bleimund, Emily	United States Department of Health and Human Services
Region of the Americas	United States of America	Bush, Laina	United States Department of Health and Human Services
Region of the Americas	United States of America	Delew, Nancy	United States Department of Health and Human Services
Region of the Americas	United States of America	Emami, Sarah	United States Department of Health and Human Services
Region of the Americas	United States of America	Finegold, Kenneth	United States Department of Health and Human Services
Region of the Americas	United States of America	Pace, Loyce	United States Department of Health and Human Services
Region of the Americas	United States of America	Snyder, Anne	United States Department of Health and Human Services
Region of the Americas	United States of America	Thomas, Gloria	United States Department of Health and Human Services
Region of the Americas	United States of America	Low, Ee Vien	University of Houston/ Ministry of Health Malaysia
Region of the Americas	United States of America	Vian, Taryn	University of San Francisco
Region of the Americas	United States of America	Arce, Antonio	Viatis
Region of the Americas	United States of America	lunes, Roberto	World Bank Institute
Region of the Americas	United States of America	Alcocer Vera, Pablo	World Health Organization (WHO)
Region of the Americas	United States of America	Balleste, Jordi	World Health Organization (WHO)
Region of the Americas	United States of America	Botwright, Siobhan	World Health Organization (WHO)
Region of the Americas	United States of America	Caccavo, Francisco	World Health Organization (WHO)
Region of the Americas	United States of America	Etienne, Carissa	World Health Organization (WHO)
Region of the Americas	United States of America	Fitzgerald, James	World Health Organization (WHO)
Region of the Americas	United States of America	Ines Porrás, Analía	World Health Organization (WHO)
Region of the Americas	United States of America	Lemgruber, Alexandre	World Health Organization (WHO)
Region of the Americas	United States of America	Mata, Alexandra	World Health Organization (WHO)
Region of the Americas	United States of America	Moreno, Ana	World Health Organization (WHO)
Region of the Americas	United States of America	Ozturk, Murat	World Health Organization (WHO)
Region of the Americas	United States of America	Perez-Gutierrez, Enrique	World Health Organization (WHO)
Region of the Americas	United States of America	Pippo, Tomas	World Health Organization (WHO)
Region of the Americas	United States of America	Rodriguez, Daniel	World Health Organization (WHO)

WHO Region	Reported Country	Full Name	Reported Affiliation
Region of the Americas	United States of America	Saenz, Carla	World Health Organization (WHO)
Region of the Americas	United States of America	Sati, Hatim	World Health Organization (WHO)
Region of the Americas	United States of America	Suazo, Martha	World Health Organization (WHO)
Region of the Americas	United States of America	Vallini, Juliana	World Health Organization (WHO)
Region of the Americas	United States of America	Schoonveld, Ed	ZS Associates
Region of the Americas	United States Virgin Islands	Lim, Christopher	World Health Organization (WHO)
Region of the Americas	Uruguay	Porcelli, María	Fondo Nacional de Recursos
Region of the Americas	Uruguay	Rodriguez Sotro, Ricardo	Ministry of Public Health
Region of the Americas	Uruguay	Sanguinetti, Ana	Ministry of Public Health
Region of the Americas	Uruguay	Benia, Wilson	World Health Organization (WHO)
South-East Asia Region	Bangladesh	Salahuddin, Md	Directorate General of Drug Administration
South-East Asia Region	Bhutan	Dhendrup, Tashi	Drug Regulatory Authority
South-East Asia Region	Bhutan	Nenda, Kezang	Menjong Sorig Pharmaceuticals Corporation Limited
South-East Asia Region	Bhutan	Peljor, Jangchhup	Ministry of Health
South-East Asia Region	Bhutan	Tashi, Ugyen	Ministry of Health
South-East Asia Region	India	Kaushik, Nalini	DevUp Global Consulting Pvt Ltd
South-East Asia Region	India	Jatkar, Archana	Indian Pharmaceutical Alliance
South-East Asia Region	India	Jain, Sudarshan	Indian Pharmaceutical Alliance and International Generic and Biosimilar Medicines Association
South-East Asia Region	India	Dhar, Biswajit	Jawaharlal Nehru University
South-East Asia Region	India	Kachroo, Kavita	Kalam Institute of Health Technology
South-East Asia Region	India	Kappoori Madhavan, Gopakumar	Third World Network
South-East Asia Region	India	Fusire, Terence	World Health Organization (WHO)
South-East Asia Region	India	Kim, Jin	World Health Organization (WHO)
South-East Asia Region	India	Shridhar, Manisha	World Health Organization (WHO)
South-East Asia Region	Indonesia	Hutabarat, Moriana	Food and Drug Agency

WHO Region	Reported Country	Full Name	Reported Affiliation
South-East Asia Region	Indonesia	Hutajulu, Togi	Food and Drug Agency
South-East Asia Region	Indonesia	Nopitasari, Dewi	Food and Drug Agency
South-East Asia Region	Indonesia	Nurcahyani, Wahyu	Ministry of Health
South-East Asia Region	Indonesia	Pahlemy, Helsy	Ministry of Health
South-East Asia Region	Indonesia	Anggriani, Yusi	Universitas Pancasila/HAI consultant
South-East Asia Region	Nepal	Sharma, Guna	Ministry of Health and Population
South-East Asia Region	Sri Lanka	Gajanayake, Chandana	State Ministry of Production Supply & Regulation of Pharmaceuticals
South-East Asia Region	Sri Lanka	Uduwawala, Kamal	State Ministry of Production Supply and Regulation of Pharmaceuticals
South-East Asia Region	Sri Lanka	De Silva, Asita	University of Kelaniya, Sri Lanka
South-East Asia Region	Thailand	Chuachantra, Thirapich	Food and Drug Administration
South-East Asia Region	Thailand	Martro, Juthathip	Food and Drug Administration
South-East Asia Region	Thailand	Akaleephan, Chutima	Ministry of Public Health
South-East Asia Region	Thailand	Jitruknatee, Anchalee	Ministry of Public Health
South-East Asia Region	Thailand	Poonpolsub, Sitanun	Ministry of Public Health
South-East Asia Region	Thailand	Suchonwanich, Netnapis	National Health commision Office (NHCO)
South-East Asia Region	Thailand	Supungul, Somruethai	National Health Security Office : NHSO
South-East Asia Region	Thailand	Oh, Cecilia	United Nations Development Programme (UNDP)
South-East Asia Region	Thailand	Ong, Leslie	United Nations Development Programme (UNDP)
South-East Asia Region	Timor-Leste	Lopes, Alipio	Ministry of Health
South-East Asia Region	Timor-Leste	Maria, Miguel	Ministry of Health
South-East Asia Region	Timor-Leste	Correia, Nelson	SAMES I.P.
Western Pacific Region	Australia	Chaston, Daniel	Australian Department of Health
Western Pacific Region	Australia	Lardner, Ellen	Australian Department of Health
Western Pacific Region	Australia	Quinn, Melissa	Australian Department of Health
Western Pacific Region	Australia	Rintoul, Andrew	Australian Department of Health
Western Pacific Region	Australia	Hill, Suzanne	Consultant

WHO Region	Reported Country	Full Name	Reported Affiliation
Western Pacific Region	Australia	Newby, David	University of Newcastle
Western Pacific Region	China	Ying-Yao, Chen	School of Public Health, Fudan University
Western Pacific Region	Fiji	Mata, Eva	World Health Organization (WHO)
Western Pacific Region	Fiji	Raikabakaba, Asaeli	World Health Organization (WHO)
Western Pacific Region	Japan	Sekitani, Yui	Ministry of Health, Labour and Welfare
Western Pacific Region	Japan	Takahashi, Yoshimitsu	Niigata university of health and welfare
Western Pacific Region	Japan	Fukuta, Keiko	Osaka University
Western Pacific Region	Japan	Akahane, Naoki	Permanent Mission of Japan to the International Organizations in Geneva
Western Pacific Region	Japan	Kamae, Isao	University of Tokyo
Western Pacific Region	Malaysia	Chung, Han Yang	Drugs for Neglected Diseases Initiative (DNDi)
Western Pacific Region	Malaysia	Hashim, A'tia	Kementerian Kesihatan Malaysia
Western Pacific Region	Malaysia	Kamaruzaman, Hanin	Malaysian Health Technology Assessment Section
Western Pacific Region	Malaysia	Haji Khalil, Fatkhiah	Ministry of Health
Western Pacific Region	Malaysia	Ku Abd Rahim, Ku Nurhasni	Ministry of Health
Western Pacific Region	Malaysia	Lee, Sit Wai	Ministry of Health
Western Pacific Region	Malaysia	Mohamed Ghazali, Izzuna	Ministry of Health
Western Pacific Region	Malaysia	Sa'ari, Noraini	Ministry of Health
Western Pacific Region	Malaysia	Shariff, Nordiana	Ministry of Health
Western Pacific Region	Malaysia	Wan Ibrahim, Wan Nor Ashikin	Ministry of Health
Western Pacific Region	Malaysia	Wong, Shui Ling	Ministry of Health
Western Pacific Region	Malaysia	Soo, Paul	World Health Organization (WHO)
Western Pacific Region	Mongolia	Bayarbold, Budragchaa	Health Insurance of Mongolia
Western Pacific Region	Mongolia	Batmunkh, Tsetsegsaikhan	Medicine and Medical Devices Regulatory Agency
Western Pacific Region	Mongolia	Amarjargal, Chojjoo	Ministry of Health
Western Pacific Region	Mongolia	Zulzaga, Zuzaan	World Health Organization (WHO)
Western Pacific Region	New Zealand	Chetwin, Suzanne	Pharmaceutical Management Agency

WHO Region	Reported Country	Full Name	Reported Affiliation
Western Pacific Region	Papua New Guinea	Salenga, Roderick	World Health Organization (WHO)
Western Pacific Region	Philippines	Guerrero, Melissa	Department of Health
Western Pacific Region	Philippines	Hao, Razel Nikka	Department of Health
Western Pacific Region	Philippines	Santillan, Melanie	Philippine Health Insurance Corporation
Western Pacific Region	Philippines	Davison, Laura	World Health Organization (WHO)
Western Pacific Region	Philippines	Escalante, Socorro	World Health Organization (WHO)
Western Pacific Region	Philippines	Salcedo, Marilyn	World Health Organization (WHO)
Western Pacific Region	Philippines	Sandbaek, Maximilian	World Health Organization (WHO)
Western Pacific Region	Philippines	Tonolete, Juan Paolo	World Health Organization (WHO)
Western Pacific Region	Singapore	Diong, Tza-Kai	Ministry of Health
Western Pacific Region	Singapore	Lin, Liang	Ministry of Health
Western Pacific Region	Singapore	Lou, Huei-Xin	Ministry of Health
Western Pacific Region	Viet Nam	Bao, Nguyen	Ministry of Health

## Annex 2: Agenda

### Fair Pricing Forum 2021

13-22 April 2021

World Health Organization, Geneva, Switzerland

#### Tuesday, April 13, 2021

1200 - 1230 (UTC) **Opening address**

**Moderator**

Clive Ondari WHO

**Speakers**

Carissa F. Etienne Pan American Health Organization and World Health Organization

Mariângela Simão WHO

Carla Vizzotti Ministry of Health, Argentina

1230 - 1345 (UTC) **Inaugural plenary** **The need for Global Public Goods and affordable access for all in the time of COVID-19 pandemic and beyond**

This session aims to highlight the need for improving current innovation systems for production of global public goods, while ensuring sustainability; and increasing global collaboration and transparency to improve pricing policies to ensure affordability of vital health products for all.

**Moderator**

Clive Ondari WHO

**Contributors**

Bjørn-Inge Larsen Norwegian Ministry of Health and Social Care Services

Anban Pillay National Department of Health, South Africa

Loyce Pace U.S. Department of Health and Human Services

Carlos María Correa The South Centre

Thomas Cueni International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

Ralph F. Ives Global Medical Technology Alliance

Sudarshan Jain Indian Pharmaceutical Alliance and International Generic and Biosimilar Medicines Association (IGBA)

Lorena Di Giano RedLAM (Latin American Network for Access to Medicines)

Mariângela Simão WHO



1400 - 1530  
(UTC) **Plenary session 2**

### **Looking back and looking forward on national transparency initiatives, pricing policy reforms and role of stakeholders**

This session will discuss recent policy reforms and initiatives targeting access barriers and affordability of medicines and health technologies. It will explore feasible ways to develop public accountability and transparency mechanisms to support efforts for improving affordable access.

#### **Moderators**

Andrew Gray	University of KwaZulu-Natal
Analía Ines Porrás	Pan American Health Organization and World Health Organization

#### **Contributors**

Mohammad A. Al-Owairdhi	Saudi Food and Drug Authority
Chen Ying-Yao	Fudan University
Martha Gyansa-Lutterodt	Ministry of Health, Ghana
Nicola Magrini	Agenzia Italiana del Farmaco, Italy
Ana Carolina Navarrete	Brazilian Institute for Consumer Protection, Brazil
Diogo Piedade	Medicines for Europe & IGBA
Roz Scourse	Médecins Sans Frontières (MSF) Access Campaign
Asita de Silva	National Medicines Regulatory Authority (NMRA), Sri Lanka

## **Wednesday, April 14, 2021**

1200 - 1330  
(UTC) **Parallel Session 1**

### **Cross-border collaborative initiatives to bring about more affordable pricing of vaccines and medicines**

This session aims to revisit various aspects of cross-border collaborative initiatives to bring about more affordable pricing of vaccines and medicines, with the purpose of exploring possible options for further enabling these initiatives.

#### **Moderator**

Fatima Suleman	University of KwaZulu-Natal
Martin Wenzl	Organisation for Economic Co-operation and Development

#### **Contributors**

Karl Claxton	University of York
James Fitzgerald	Pan American Health Organization and World Health Organization
David Kiambi Mutuerandu	United Nations International Children's Emergency Fund (UNICEF)
Yannis Natsis	European Public Health Alliance
Sonia Tarragona	Ministry of Health, Argentina
Inneke Van de Vijver	Institut national d'assurance maladie-invalidité, Belgium
Brenda Waning	Global Drug Facility, Stop TB Partnership at UNOPS

1200 - 1330  
(UTC)

## Parallel Session 2

## Promoting transparency for accountable medical innovation

This panel will explore transparency of the building blocks of knowledge furthering innovation, transparency of the costing of an end-product, and transparency to ensure accountability of incentives to achieve fair pricing. This session will highlight the need for action around transparency in ensuring accountability for incentives to achieve fair prices, data systems needed to analyze inputs throughout the value chain, and impact of transparency on enabling the right innovations for public health priorities.

### Moderator

Sabine Vogler Austrian Public Health Institute GÖG, Austria

### Contributors

Anne Hendrickx	Union Nationale des Mutualités Socialistes - Solidaris
Lenias Hwenda	Medicines for Africa
Isao Kamae	University of Tokyo
Pauline Londeix	Observatoire Transparence Médicaments
Claudia Martinez	Access to Medicines Foundation
Corey Salsberg	Novartis and IFPMA

1200 - 1330  
(UTC)

## Parallel Session 3

## Fair pricing and affordability of medical devices including in vitro diagnostics

This session will review challenges faced by countries when trying to achieve affordable pricing information of medical health technologies, such as CT scanners glucose monitoring, and oxygen delivery systems. To explore potential solutions, it will highlight the complexity of negotiation of fair prices that cover device/Dx cost, reagents and other consumables, maintenance and technical support costs and capital expenses vs operating expenses.

### Moderator

Alexandre Lemgruber Pan American Health Organization and World Health Organization  
Adriana Velazquez WHO

### Contributors

Murilo Contó	Boston Scientific and representative of implantable medical devices industry
Keiko Fukuta	Ministry of Health, Labour and Welfare (MHLW), Japan
Cristiane Jourdan Gomes	Agência Nacional de Vigilância Sanitária (ANVISA), Brazil
Iñaki Gutiérrez	Health Technology Assessment International
Thierry Hounbo	Clinical Engineering and Policy Researcher at Benin Ministry of Health
Claudio Meirovich	WHO Regional Office for Europe
Shauna Mullally	Global Clinical Engineering Alliance
Ledina Picari	Ministry of Health and Social Protection, Albania
Gabriela Prada	Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA)
Beatrice Vetter	Foundation for Innovative New Diagnostics (FIND)

# Thursday, April 15, 2021

1200 - 1330  
(UTC)

## Parallel Session 4

### Fairness before the finish line: Placing access conditions on incentives for innovation

Conditions for enabling fair prices can be built in as part of incentives for innovation. The resulting health technologies might need to meet specified target product profiles, disclose clinical trial data, license research tools, or provide guarantees of pricing or volume. This session will analyze learnings from experiences on conditional innovation incentives and key elements of success, aiming to identify potential applications of conditionality to other contexts and needed areas of process engagement.

#### Moderator

Anthony So

John Hopkins Bloomberg School of Public Health

#### Contributors

Michelle Childs

Drugs for Neglected Diseases initiative (DNDi)

Patrick Holmes

Pfizer and IFPMA

Aaron Kesselheim

Harvard PORTAL

Santiago Torales

Comisión Nacional de Evaluación de Tecnologías de Salud, Argentina

Jaume Vidal

Stichting Health Action International

Emma Wheatley

Coalition for Epidemic Preparedness Innovations (CEPI)

Ed Whiting

Wellcome Trust

1200 - 1330  
(UTC)

## Parallel Session 5

### Price and value of health products

This session seeks to understand what the meanings of ‘value’ to different stakeholders are when it comes to pricing pharmaceutical products, including how to include health opportunity costs, budget impacts, equity and other factors. Through shared experiences, it will explore the benefits, drawbacks and challenges of using value assessment to inform pricing. It will explore ways for supporting government authorities in countries without mature system to perform HTA so that they could perform value assessments more effectively to inform pricing.

#### Moderator

Sarah Garner

WHO Regional Office for Europe

Steve Morgan

University of British Columbia

#### Contributors

Brian Asare

Ministry of Health, Ghana

Vânia Canuto

Dept Management & Incorporation of Technologies in Health, DGITS Brazil

Karl Claxton

University of York

Mouna Jameleddine

National Authority for Assessment and Accreditation in Healthcare, Tunisia

Emma Klatman

Life for a Child

Valérie Paris

Haute Autorité de Santé (HAS), France

Richard Torbett

Association of the British Pharmaceutical Industry and IFPMA

1200 - 1330  
(UTC)

### Parallel Session 6

### Tools, standards and solutions for improving price transparency

This session will focus on how to implement the provisions WHA 72.8 with special focus on price transparency and discuss: (1) What type of norms and standards including internationally accepted terminology are needed for reporting “net prices of health products” that can allow valid international comparisons? (2) what are the key processes and element of building a functional price information sharing platform? (3) which type of medicines price (reimbursement) information is most valuable in practical terms to governments to strengthen pricing intervention including negotiation with manufacturers.

#### Moderator

Klara Tisocki

WHO

Taryn Vian

University of San Francisco

#### Contributors

Tania Cernuschi

WHO

Marg Ewen

Stichting Health Action International

Melissa Guerrero

Department of Health, the Philippines

James Love

Knowledge Ecology International

Gergely Németh

EURIPID

Ellen 't Hoen

Medicines Law & Policy

## Tuesday, April 20, 2021

1200 - 1330  
(UTC)

### Parallel Session 7

### Making the public sector more effective stewards of innovation and access

The public sector can play a more direct role, such as through procurement or production, of key health commodities to ensure effective stewardship to achieve fair pricing. The public pays a substantial role in funding innovation, either upfront for R&D or after innovations reach the market, or more often twice for these products (not counting the investment in building the human capital and capacity behind such innovation). This significant public investment provides the means for aligning innovation with public health priorities and incentives for innovation to achieve fair prices. How can public sector financing complement private sector initiative to encourage greater R&D productivity, more cost-effective pricing, and innovation of these products as well to achieve fairer pricing?

#### Moderator

Jorge Bermudez

Escola Nacional de Saúde Pública

Mariana Mazzucato

University College London

#### Contributors

Peter Beyer

WHO

Dana Brown

Next System Project

Francisco Rossi

IFARMA Foundation

Maja Sercic

Medicines for Europe and IGBA

Netnapi Suchonwanich

National Health Security Office, Thailand

Martin Van Trieste

CivicaRx

1200 - 1330  
(UTC)

### Parallel Session 8

### Regulating excessive pricing and returns along the supply and distribution chain

This session seeks to better understand the drivers of excessive pricing and returns in the pharmaceutical industry. The session will identify to what extent could government interventions through competition laws and pricing regulations address the risks of excessive pricing, as well as whether additional instruments are needed to advance universal access to essential medicines and public welfare.

#### Moderator

Ruth Lopert

Organisation for Economic Co-operation and Development

Aukje Mantel-Teeuwisse

Utrecht Centre for Pharmaceutical Policy and Regulation

#### Contributors

Frederick Abbott

Florida State University

Antonio Capobianco

Organisation for Economic Co-operation and Development

Dimitra Lingri

Supreme Court-EOPYY, Greece

Leontien Ruttenberg

IMRES

Ellen 't Hoen

Medicines Law & Policy

Adrian van den Hoven

Medicines for Europe and IGBA

Mayra Vasquez

National Agency for Healthcare Providers, Colombia

1200 - 1330  
(UTC)

### Parallel Session 9

### Judicialization of Health Care: Challenges and perspectives

Judicialization of health care refers to the reliance on courts and judicial processes to resolve litigations brought on by individuals to demand the provision of certain pharmaceuticals and medical treatments by the State based on rights-to-health claims. This session aims to analyze the causes of the judicialization of health and its effects on health systems in Latin America. It will explore how health interventions and services could be prioritised with the support of laws, regulations, and scientific evidence, and if these are potential alternatives for judicialization.

#### Moderator

Marisa Aizenberg

Observatory on the Right to Health, Universidad de Buenos Aires

Juan Ignacio Correa

Max Plank Institute for Innovation and Competition

#### Contributors

Tatiana S. Andia

Universidad de los Andes

Silvina Andrea Bracamonte

The Federal National Civil and Commercial Court No. 1 (Argentina)

José Luis Cassinerio

The Federal National Civil and Commercial Court No. 4 (Argentina)

Roberto lunes

World Bank Institute

Mouna Jameleddine

National Authority for Assessment and Accreditation in Healthcare, Tunisia

Tomás Pippo

Pan American Health Organization and World Health Organization

José Fernando Reyes Cuartas

Constitutional Court of Colombia

## Wednesday, April 21, 2021

1200 - 1330  
(UTC)

### Plenary session 3

### Moving towards fair prices by public health-driven application and management of Intellectual Property

This session will cover recent policies related to application and management of intellectual property to promote equitable access to health technologies, including C-TAP and TRIPS waiver. It aims to promote a better understanding on how different initiatives could support the achievement of the same goal.

#### Moderator

Cecilia Oh

United Nations Development Programme

#### Contributors

Mustaqeem Da Gama

South African Permanent Mission to the World Trade Organization

Erika Dueñas

WHO

John R. Fulton

BioNiagara

Charles Gore

Medicines Patent Pool

Komal Kalha

IFPMA

Sangeeta Shashikant

Third World Network

Antony Taubman

World Trade Organization

Luis Villarroel Villalón

Corporacion Innovarte

## Thursday, April 22, 2021

1200 - 1310  
(UTC)

### Plenary session 4

### Breaking barriers to access and affordability: Need for concerted global action

This session will synthesise the outputs of the various sessions and identify key areas emerging from discussions, including potential solutions, areas of collaboration, and promising practices to improve transparency of markets for health products.

#### Moderator

Klara Tisocki

WHO

Emiliano Melero

Ministry of Health, Argentina

#### Contributors

Suerie Moon

Global Health Centre, Graduate Institute of International and Development Studies

Anban Pillay

National Department of Health, South Africa

Marcel van Raij

Ministry of Health, the Netherlands

Anthony So

John Hopkins Bloomberg School of Public Health

Fatima Suleman

University of KwaZulu-Natal

Sonia Tarragona

Ministry of Health, Argentina

1310 - 1330  
(UTC)

**Closing remarks**

**Moderator**

Clive Ondari                      WHO

**Speakers**

Carla Vizzotti                      Ministry of Health, Argentina

Philippe Duneton                      Unitaid

Mariângela Simão                      WHO

### Annex 3: Members of Fair Pricing Forum 2021 preparatory working groups

#### List of experts for preparatory working group on topic I:

Exploring pricing approaches sensitive to health systems' ability to pay and to the need for achieving universal coverage of pharmaceutical products


<b>Angela Ackon</b> Director, Pharmaceutical Service Ministry of Health Ghana	<b>Sara Amini</b> Head of International Value & Access Policy & Advocacy International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
<b>Karl Claxton</b> Professor of Economics The University of York The United Kingdom	<b>Gabriela Svecova Cvekova</b> State Advisor Ministry of Health Slovakia
<b>David Gaugh</b> Representing the International Generic and Biosimilar medicines Association Senior Vice-President for Sciences and Regulatory Affairs of the U.S. Association for Accessible Medicines	<b>Mouna Jameleddine</b> Head of HTA Department Instance Nationale de l'Evaluation & de l'Accrédiation en Santé (INEAS) Tunisia
<b>Diana Ina Lauritzen</b> Special Advisor, Pharmaceutical Officer Danish Medicines Agency Denmark	<b>Dimitra Lingri</b> Head of Legal Department The National Organization for the Provision of Health Services (EOPYY) Greece
<b>Yannis Natsis</b> Policy Manager for Universal Access & Affordable Medicines European Public Health Alliance (EPHA) Management Board member, European Medicines Agency (EMA)	<b>David Newby</b> Associate Professor at the School of Biomedical Sciences and Pharmacy University of Newcastle Australia
<b>Marcela Pontes</b> Executive Secretariat of Pharmaceutical Market Regulation Chamber Brazilian Health Regulatory Agency Brazil	<b>Fatima Suleman</b> Chairperson, National Medicines Pricing Committee, National Department of Health Professor, University of KwaZulu-Natal, Durban, South Africa
<b>Sonia Gabriela Tarragona</b> Undersecretary for Medicines and Strategic Information Ministry of Health Argentina	



**List of experts for preparatory working group on topic II:**  
Aligning incentives for pharmaceutical innovation

<b>Deena Alasfoor</b> HTA Committee Ministry of Health Oman	<b>Helga Festøy</b> Head of Unit, Safe Use Norwegian Medicines Agency Norway
<b>Komal Kalha</b> Head of Intellectual Property and Trade Policy International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)	<b>Mariana Mazzucato</b> Professor in Economics of Innovation and Public Value University College London The United Kingdom
<b>Mirna Metni</b> Controller Pharmacist Medical Control Department Lebanese National Social Security Fund Lebanon	<b>Suerie Moon</b> Co-Director, Global Health Centre The Graduate Institute of International and Development Studies (IHEID) Switzerland
<b>Daudi Msasi</b> Chief Pharmacist Pharmaceutical Services Ministry of Health Tanzania	<b>Maja Sercic</b> Representing the International Generic and Biosimilar medicines Association Policy & Science Manager Medicines for Europe
<b>Anthony So</b> Founding Director Innovation+Design Enabling Access (IDEA) Initiative Johns Hopkins University United States of America	<b>Biswajit Dhar</b> Professor Centre for Economic Studies and Planning School of Social Sciences Jawaharlal Nehru University India
<b>Jaume Vidal</b> Senior Policy Advisor Health Action International Netherlands	<b>Santiago Torales</b> Health Research Directorate Ministry of Health Argentina

9789240038585



9

789240

038585